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ABSTRACT 
Engineered nanomaterials (ENM) have emerged as attractive and promising candidates for a 
wide range of advanced applications including in particular in medicine. However, the 
increased development of ENM raises the need to carefully assess their potential impact on 
human health and environment. For that, detailed evaluation of the intrinsic and biological 
identity of ENM is required for the safe design and use of these materials. To this effect, the 
present thesis focuses on the synthesis and biocompatibility assessment of two different classes 
of nanomaterials, dendrimers and superparamagnetic iron oxide nanoparticles (SPIONs), 
promising future nanomedicines for drug delivery and imaging agents in magnetic resonance 
imaging (MRI). Assessment was performed on primary human monocyte derived macrophages 
(HMDM), primary human bronchial epithelial cells (PBEC), and cell lines. Hereby an insight 
on the impact of these materials on the immune system and on their promising and potential use 
as nanomedicines has been obtained. Furthermore, we attempted to use systems biology 
approaches as a novel tool to identify possible hazard of ENM by using next generation 
sequencing RNA-Seq and computational tools. Finally, we assessed the bio-nano-interactions 
by evaluating the effect of the protein corona on the targeting capabilities of ENM and their 
behaviour. Importantly, the ENM were extensively characterized, using different techniques 
prior to the toxicity studies. In Paper I, we evaluated the biocompatibility of a library of 
polyester dendrimers based on 2,2-bis(methylol)propionic acid (bis-MPA) including  
dendrimers with two different surface functionalization, hydroxyl and carboxylic end groups, 
and two commercial polyamidoamine dendrimers (PAMAM) with amine and hydroxyl end 
groups. We found excellent biocompatibility for the entire hydroxyl functional bis-MPA 
dendrimer library, whereas the cationic, but not the neutral PAMAM exerted dose and time 
dependent cytotoxicity in the cell models tested. In paper II, using system biology approaches 
and bioinformatics tools, we were able to identify and validate the toxicity mechanism of PBEC 
exposed to PAMAMs dendrimers at low doses. Our studies showed that PAMAM-NH2, but not 
PAMAM-OH, caused down-regulation of cell cycle-related genes and cell cycle arrest in S-
phase. Our findings provide evidence of the beneficial use of these new toxicology tools for the 
future risk assessment of nanomaterials. SPIONs have emerged as promising nanomaterials for 
biomedical applications, due to their excellent magnetic properties, chemical stability and 
biocompatibility. In paper III, ultrasmall superparamagnetic iron oxide nanoparticles 
(USIRONs) were prepared by a one-pot aqueous approach by using Fe(OH)3 as iron precursor, 
vitamin C as reducing agent, and dehydroascorbic acid (DHAA) as capping agent. We showed 
that USIRONs present high crystallinity, long-term colloidal stability, enhanced saturation 
magnetization, and exhibit excellent biocompatibility as demonstrated in the toxicity evaluation 
using primary HMDM. When nanoparticles are in contact with physiological fluids, adsorption 
of proteins on the surface of the nanomaterial will occur, resulting in the establishment of a 
protein corona. Whether the protein corona will affect the targeting capabilities of the ENM 
was investigated. In paper IV, folic acid (FA)-conjugated iron oxide nanoparticles with 
poly(ethylene glycol) (PEG) or SiO2 surface coatings were synthetized. We evaluated their 
biocompatibility and specific targeting effects on HMDM and on ovarian cancer cells, that over 
express the folic acid receptor. Notably, we demonstrated the nanoparticles (NPs) were non-
toxic to cells and that FA specific uptake was observed only for the FA iron oxide SiO2 coated 
NPs in the presence of serum proteins. Our studies contribute to the development of new 
nanomaterials and their applications, which may facilitate the clinical translation of the 
nanomedicines. 
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1 INTRODUCTION 
 
1.1 NANOMATERIALS  
1.1.1 Biomedical applications of nanomaterials 
Nanotechnology is a rapidly growing discipline that offers a wide range of applications. 
Their novel physicochemical properties make nanomaterials highly attractive and 
promising for medical development,
1
 with potential benefits for treating and diagnosing 
cancer. Some of these materials already have reached the clinic.
2,3
 However, their 
promising characteristics may also yield unexpected adverse effects on human health 
and the environment
4
. Therefore, careful toxicity evaluation is needed in order to 
provide knowledge for the safe design of these materials for such applications. 
 
The unique chemical and physical properties of engineered nanomaterials are attributed 
to their small size that gives rise to significantly different properties from conventional 
materials on the microscale level.
5
 These properties, such as narrow size distribution, 
composition, surface structure, shape, aggregation, and solubility, influence the 
mechanical, electrical, optical, and magnetic properties, as well as the chemical 
reactivity of these materials.
6,7
 These distinct properties make ENM offer a wide range 
of opportunities and applications, covering both the engineering and biomedical 
sectors. Our curiosity is focused on the extraordinary potential that the utilization of 
ENM offers in improving clinical diagnosis and in various branches of biomedical 
research.   
 
The field of nanomedicine encompasses the applicability of nanotechnology to 
medicine, with the goal to design multifunctional nanoparticles with desirable 
properties for medical applications, including diagnostics, imaging, drug delivery, and 
other health- associated applications.
8
 Nanomedicines are generally based on 
multifunctional particles that can encapsulate active therapeutics within their nanoscale 
framework, and which are capable to release the therapeutic payload in a specific 
manner. Most often, such constructs increase the bioavailability of the drug and can be 
used to control the pharmacokinetics and biodistribution of the active compound. 
Liposomes, protein particles, and polymer-drug conjugates are examples of approved 
therapeutic nanomedicines used in clinics. Furthermore, nanoscale contrast agents are 
also used in clinical radiology, such as SPIONs and dendrimers that are used to 
enhance resolution in magnetic resonance imaging.
2, 9, 10
 .  
 
Nanotechnology is expected to make an important contribution to cancer prevention, 
detection, diagnosis, imaging, and treatment (cf. Figure 1). Today all conventional 
cytotoxic therapies are not completely effective.
11
  Large proportions of new emerging 
drug candidates are only poorly water-soluble such as docetaxel (Taxotere), which is 
commonly used for the treatment of breast and lung cancer. Therefore, the development 
of drug nanocarriers for poorly soluble pharmaceuticals is an important task.
12
 
Theragnostics is the treatment approach that combines therapeutic delivery systems 
 2 
with diagnostics (imaging), with the aim to monitor the treatment and to improve drug 
efficacy and safety,
13
 developing both prognosis and therapy.
14
 Nanomaterials are 
particular relevant for cancer treatment, which may offer advantage over traditional 
therapies by providing higher efficacy and lower toxicity of treatment.  
 
Nanomedicines that exhibit extended circulation time may accumulate passively into 
tumor tissue.  This process is known as enhanced permeability and retention (EPR) 
effect.
15,16
 It refers to the propensity to nano-and micro- size therapeutic agents to 
accumulate in tumor tissue, providing significant advantages compared with low 
molecular weight agents
17
.  However, for a successful delivery of nanomedicines, 
several factors should be taking consideration: i) the influence of the EPR effect as 
previously mentioned, ii) the permeability of the tumor vasculature, iii) the blood flow 
to the tumor, iv) the intratumoral pressure, and v) the nature of the barrier between the 
tumor cells and the extracellular matrix.
15
  
 
In recent years, there has been an increase in the different imaging technologies and 
their applications.
18, 19
 Molecular imaging offers the opportunity to obtain information 
on cellular function and molecular processes in living organisms by both in vitro and in 
vivo systems, with high sensitivity and specificity. Examples of molecular imaging 
systems include computed tomography (CT) imaging, optical imaging, magnetic 
resonance (MR) imaging, single photon emission computed tomography (SPECT), 
and position emission tomography (PET). Notably, among the different techniques, 
CT and MRI provide higher resolution than the other modalities. Moreover, molecular 
imaging techniques can be used in diagnoses of diseases such as cancer, by enabling to 
visualize tumours in the body.
20
  Current advances in nanotechnology offer to use 
engineered nanomaterials as molecular imaging agents. Due to their possibility to be 
designed with multifunctionality, which permits different imaging modalities,
21
 and to 
perform target diagnosis and therapeutics, several nanomaterials have been studied for 
cancer treatment22 including polymers, dendrimers, liposomes, micelles, magnetic 
nanoparticles,  etc.
23
   A detailed description of the materials used in this thesis and 
their biomedical applications is given in the following. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The application of nanotechnology in medicine. The image is reproduced from Fadeel et 
al.
24
 with permission from Journal of Internal Medicine.  
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1.1.2 Dendrimers  
Dendrimers are highly branched and monodisperse macromolecules with exact 
structure, placement of functionally and dimensions, whose name comes from the 
Greek word “Dendros” meaning tree and “meros” meaning part. In 1978, when 
Vögtle
25
 et al. described the first synthesis of dendritic materials based on 
polypropylene-amine structure. A few years later, in 1985, two parallel studies 
published by Tomalia et al.
26 
and Newkome et al.
27
 , pioneers of dendrimer technology, 
described, polyamidoamine (PAMAM) dendrimers and poly(etheramide) structures, 
respectively. In 1990, a new type of dendrimer based on the convergent method was 
presented by Hawker and Frechét, the poly(benzylether) dendrimer.
28
 Today, the 
dendritic family can be divided into sub-groups based on their disperse frameworks, i.e. 
monodisperse dendrimers and dendrons, and polydisperse dendrigraft, hyperbranched 
polymers, and dendritic linear hybrids
29
 (cf. Figure 2). 
 
Divergent and convergent growths are two conventional approaches used in the 
synthesis of dendritic structures. In essence the divergent method grows the structure 
from the interior outwards, and in the convergent method the structure is grown from 
the exterior inwards.
30
  Several more optimized methods for dendrimer synthesis have 
since then been evolved, including the orthogonal growth, double exponential growth, 
and double stage convergent growth strategies.
29
  
 
Today several dendrimers have reached the market, including PAMAM (Dendritech), 
which is composed of a diamine core linked with methyl acrylate, poly(propylene 
imine) (PPI) (Symo-Chem BV), and 2,2 bis(hydroxymethyl)propionic acid (bis-MPA) 
dendrimers (Polymer Factory).  
 
 
 
 
 
Figure 2. Schematic picture of sub-classes in the dendritic family. The image is reproduced from 
Carlmark et al.
30
  with permission of The Royal Society of Chemistry. 
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For therapeutic applications, dendrimers offer advantages over other classes of 
nanomaterials. Unlike traditional polymers, dendrimers are monodisperse, which is a 
crucial property to ensure the reproducibility of the PK and BioD studies
31
. They 
present broad design possibilities with high control of size, shape, solubility, molecular 
weight, and specific control of the exact position of functional groups.
32
  In addition, 
dendrimers with sufficient hydrophilicity, unlike polymer micelles and liposomes, do 
not have a critical micelle concentration (CMC).  Therefore, dendrimers cannot 
disintegrate upon dilution. All these features clearly distinguishes these structures as 
unique carriers in therapeutic applications.
33
 
 
Dendrimers have often been referred to as equivalents of “proteins” due to their size, 
globular structure, and exact molecular weight.
34
 Despite the similarities between 
dendrimers and globular proteins, dendrimers have rigid structures as determined by 
covalent bonds, and represent a 3D structure with interior core and an exterior with 
controlled surface functionality.  
 
The polyester dendrimers based on the bis-MPA scaffold were originally described by 
Ihre et al.
35
 and are considered promising materials for biomedical applications
30
, due 
to their hydrolytically degradable structure and good biocompatibility.
36, 37
 Indeed, the 
group of Fréchet et al. have investigated the use of polyester dendrimers for therapeutic 
applications in several publications, such us efficient drug delivery carriers of 
doxorubicin (DOX) in vivo
38
 and dendrimers for targeted positron emission 
tomography (PET).
39-41
 Our recent studies further demonstrated their biocompatibility 
in both, primary human derived macrophages (HMDM) and cancer cell lines.
37
 
Furthermore, Wu et al. explored the formation and the cytotoxicity of 
chemotherapeutic delivery vehicles constructed from four different amphiphilic linear-
dendritic hybrid block copolymers in primary human macrophages on breast cancer 
cells. Overall, the study showed that micelles in the size range of 100 nm had a loading 
efficiency of (DOX) up to 22%. The resulting carriers were evaluated as passive drug 
delivery vehicles and the results demonstrated that they exhibit superior drug efficacy 
and a higher apoptosis inducing capacity as compared to free DOX.42 These results 
further confirm the promising use of these materials as drug delivery agents. To date, 
the FDA has not yet approved any dendritic carrier for drug delivery applications.
43
 
 
PAMAM dendrimers are one of the most studied dendrimer structures. The surface of 
PAMAMs can be modified with different functional groups that allow them to be 
explored in a multitude of biomedical applications including; i) drug delivery systems 
(DDS), ii) transfection systems (Suprafect), and iii) contrast agents for PET, MRI, and 
CT. PAMAMs are non-degradable materials and typically present amine groups on the 
surface.  Cationic PAMAM dendrimers have been associated with higher cytotoxic 
response than non-anionic, small cationic or neutral dendrimers.
44
   In order to use 
PAMAMS as nanomedicine, further surface functionalization is required to achieve 
superior biocompatibility. PAMAMs have been used i)  as templates or stabilizers for 
preparation of inorganic nanomaterials,
45
 ii) to encapsulate or conjugate a wide range 
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of drugs, such as paclitaxel,
46, 47
 methotrexate
47
 among others, and iii) for targeted drug 
delivery. For instance, intravenously injected N-acetyl-L-cysteine (NAC) conjugated 
polyamidoamine dendrimers were able to effectively accumulate in activated microglia 
and astrocytes in the brain of young rabbits with cerebral palsy. The drug delivery 
vehicle suppressed neuroinflammation and improved their motor function as compared 
with the free-drug or PAMAM alone.
48
  Dendrimer-based contrast agents for MRI 
have remarkable potential due to their flexible nature and high relaxivity properties.
49
 
Dendrimers provide advantages compared to gadolinium chelated agents due to their; 
i) superior r1 relaxivity values
50
 and ii) tunable kinetics (archived by specific 
chemistry)
51
. Some examples illustrating these features have been reported.  For 
instance Peng et al. showed that G5-PAMAM dendrimer-entrapped gold nanoparticles 
(DENPs) can be used for tumor imaging by CT contrast agents. 
52
 Li et al. synthesized 
multifunctional Gd-Au DENPs that were effectively used for dual-mode MR/CT 
imaging of tumors.
53
 At present, no targeted contrast agent is available for clinical 
MRI. Wi et al. synthesized a new CLT1 targeting contrast agent based on a stable 
macrocyclic Gd(III) chelate, Gd-DOTA. The CLT1 targeted contrast agent CLT1-dL-
(Gd-DOTA)4 linked via a generation 1 lysine dendrimer presented high specificity 
for a prostate tumor model and effective MR imaging in vivo.
54
 However, further 
studies are required to develop multifunctional nanoparticles for molecular imaging of 
different types of cancer. 
 
1.1.3 Magnetic nanoparticles  
Magnetic nanoparticles (MNPs) are a class of engineered nanomaterials that can be 
manipulated by external magnetic fields and are considered as one of the most 
important classes of nanomaterials today due to their unique physical properties
55
. 
MNPs are commonly composed from magnetic elements such as iron, nickel, cobalt, or 
metal oxides. Indeed, superparamagnetic iron oxide nanoparticles (SPIONs) have 
emerged as one of the key nanomaterials for biomedical applications, with a potential 
to create future medicines such as cancer theranostics. This is due to their excellent 
magnetic properties, high chemical stability, excellent colloidal stability, and good 
biocompatibility.
56
 Altogether, SPIONs are potential candidates for improving contrast 
enhancement in magnetic resonance imaging (MRI), hyperthermia
57
, molecular 
detection and drug delivery.
58
  
 
Iron oxide NPs are being used in clinical trials as contrast agents in magnetic resonance 
imaging (MRI),
59
 a powerful tool for non-invasive and non-destructive diagnostic 
applications in various clinical and biomedical settings. Briefly, imaging contrast of 
MR is based on the different relaxation times of water protons in tissue. To achieve 
superior images, contrast agents are used to induce changes  in  the relaxation time.
60
 
SPIONS are known as T2 (transversal relaxation time) agents (negative contrasts 
agents) and paramagnetic agents such as gadolinium and manganese chelates are 
considered T1 (longitudinal relaxation time) agents (positive contras agents). Indeed, 
most of the paramagnetic contrast agents are based on gadolinium ions Gd
3+
, which 
accelerate proton relaxation, and which are often employed to reveal physiological and 
pathological structural details of tissues.  Their efficacy will depend on the values of the 
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r1- and r2-relaxivities of these chelates and their pharmacokinetics.
61
 Besides Gd
3+
-
assisted 
1
H MRI techniques, contrast agents based on 
19
F-NMR agents
62
 are emerging 
as attractive candidates due to the high sensitivity of the 
19
F, low  background signal, 
extraordinary gyromagnetic ratio, good biocompatibility, and high natural 
abundance.
63-65
 However, in this section emphasis is given on SPIONs, as they 
represent part of the materials evaluated in this thesis. 
Several methods for the synthesis of magnetic nanoparticles have been proposed. 
SPIONs are based on an iron oxide core and are coated by either inorganic materials 
such as gold or silica or organic materials such as polymers, phospholipids, or 
polysaccharides.
66
 The two major iron oxide phases used are mainly composed by 
magnetite (Fe3O4) and maghemite (-Fe3O4) and are often synthetized in sizes smaller 
than 5-20 nm (the ultra small yes, but those are not clinically approved).  In these sizes, 
smaller than the single domain limit, iron oxide NPs exhibit superparamagnetic 
behaviour at room temperature.
55
 Therefore, in absence of an electromagnetic field, the 
overall magnetic moment will be zero.
67
 
 
Different methods are applied to synthetize iron oxide nanoparticles. Among them, the 
most commonly used approaches include i) co-precipitation;
68
 that allows for the 
preparation of large quantities of nanoparticles in one single batch, ii) sol-gel 
synthesis,
69
 iii) thermal decomposition of precursors, iv) hydrothermal reactions,
70
 etc.  
Additionally, a wide range of strategies has been proposed to functionalize MNPs for 
their adequate biomedical applications. 
71
 Furthermore, targeting ligands, such as 
peptides, monoclonal antibodies, coupled to the polymer surface of SPIONs, allow the 
nanoparticles to recognize specific tissue signatures and to act as drug-delivery 
system.
72
 As a result of their final size, MPNs can be classified as a: i) micrometre size 
paramagnetic iron oxide (MPIO), ii) superparamagnetic iron oxide, SPIO particles with 
diameter ≥ 50 nm, and iii) ultrasmall superparamagnetic iron oxide, USPIO with 
smaller diameters.
73
  
 
To date, several classes of SPIONs have been developed. The medical use of magnetic 
iron oxide nanoparticles has been approved by the European Medicines Agency 
(EMA), and the US Food and Drug Administration (FDA). 
74
 Hofmann-Amtenbrinka et 
al. review examples of commercial iron oxide NPs used as contrast agents. This 
includes Lumiren® (≥ 300 nm (+ agent)) and Gastromark® (ferumoxsil) for bowel 
imaging, Endorem© and Feridex IV© used as a spleen and liver imaging agents, 
USPIO such as Sinerem© (40 nm (- agent)) and Supravist© (25nm), and SPIONs like 
Resovist© (100-200 nm) (- agent)
66
 . However, some of them have been currently 
removed from the market.
2
  
 
The current research of SPIONs mainly involves in vivo drug delivery, MRI, and 
hyperthermia.
73
 The final applicability of the MNPs in biological systems mainly 
depends on their plasma half-life, their final biodistribution, and their possible side 
effects.  Moreover, it is still not well understood which are the parameters responsible 
for preventing or allowing the carriers to reach the specific target. One possible 
explanation could be the different biological identity formation (protein corona) of 
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nanoparticles when they are in contact with biological fluids. Further studies are 
required to address this important question. However, several ligands have been 
coupled to nanoparticles for enhancing drug delivery efficiency. Tietzer et al. 
synthetized a novel magnetic chemotherapeutic carrier-system with a size < 200 nm, 
that targets mitoxantrone efficiently in tumours in vivo and efficiently treated those 
tumours implanted in the limbs of rabbit, leading to complete tumour remissions.
75
 
Targeted therapy with MRI nanoparticles provides a suitable tool for local energy 
deposition and heating of cancer cells.
2
 
 
Despite the fact that the FDA and EMA have already approved MNs as MRI contrast 
agents, the intrinsic proprieties of this material that determine the optimal factors 
required for biomedical applications are still not sufficiently well understood.
55
 For the 
safety evaluation of these nanomaterials, cytotoxicity end points need to be considered. 
This includes cellular uptake, final fate of nanoparticles, and mechanism of action and 
biodegradation of the nanomaterial. More details on the design of safe nanomaterials 
will be discussed in the following section. 
 
 
1.2 NANOTOXICOLOGICAL ASSESSMENT OF NANOMATERIALS 
1.2.1 Overview  and  immunotoxicity 
Nanomaterials offer a great potential for a wide range of medical applications. 
However, there is the concern that human exposure of nanoparticles could lead to 
significant adverse biological outcomes in health and environment. 
2
 Nanotoxicology is 
emerging as a scientific discipline attempting to investigate the interactions of 
engineered nanomaterials with biological system at the nanoscale level by providing 
knowledge on the safety assessment of nanomaterials.
3
 Oberdörster et al. identified 
essential factors in nanotoxicology that need to be addressed for the safety assessment 
and future development of nanotechnologies. This includes dose metrics, exposure 
routes, and biodistribution of nanomaterials. Remarkably, he emphasized the 
importance of nanoparticles with well-defined physicochemical properties, and the 
validation of the conventional in vitro assays employed.
76
 
 
Understanding the interactions of nanomaterials with relevant biological systems is a 
critical factor in the safe and sustainable development of nanotechnology for 
biomedical use.
77
 Indeed nanomaterials may be distributed in the body via the 
lymphatic system where immunological reaction can occur. The primary focus of the 
immune systems is to protect against foreign materials, including particles. Therefore, 
is important to investigate the nano-immuno interactions, especially for nanoparticles 
that are intended to administration into systemic circulation as it is well known that 
particles in the blood are rapidly cleared by cells of the reticuloendothelial system in 
the liver and spleen.
78
 Notably, the use of in vitro tests involving primary cells is of 
particular relevance, as these model systems are closer to the in vivo situation.
79
 
Exposure of nanomaterials may induce immunotoxicity resulting in harmful effects to 
the immune system. Notably, macrophages are key players in the innate immune 
response, as these cells are capable of phagocytosing micro- and nano-particles.  The 
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recognition of the nanoparticles by the immune cells may play an important role. Based 
on the intrinsic properties of nanomaterial, the nano-immuno interactions can be 
controlled.
80
 Some examples are illustrated (cf. Figure 3). 
 
As summarized by Kunzman et al.  nanoparticles can be modulated for desired 
applications; i) functionalization of USPIONs with PEG may reduce uptake by 
macrophages leading to increase circulation time and ii) functionalization of SPIONs 
with ligands that are recognized by immune cells may enhance the uptake in cells.
79
 
Bhattacharjee et al. showed the effect of surface charge and cellular uptake. 
Demonstrating that negatively charged silicon nanoparticles increased the phagocytosis 
of silicon nanoparticles by rat alveolar macrophages while positively charged and 
neutral nanoparticles reduced the phagocytic ability of macrophage.
81
 
 
Importantly, Jones et al. recently, showed that the rate of nanoparticle clearance 
depends on the global status of the immune system. The study highlighted the 
importance of choosing appropriate in vivo models for pre-clinical evaluation of 
nanomedicines.
82
 
 
 
 
 
 
 
 
Figure 3. The effect of the intrinsic properties of nanoparticles on immunogenicity. The image is 
reproduced from Elsabahy et al. 83 with permission of The Royal Society of Chemistry. 
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Understanding the process of clearance is a key to controlling the biodistribution of 
nanoparticles for medical imaging and drug delivery applications, and may also be 
relevant to the understanding of adverse effects of engineered nanomaterials. 
Importantly, nanomaterials could lead to indirect “secondary” effects. For that reasons 
evaluations of nanoparticle safety should consider both, direct and indirect effects, in 
order to avoid any potential risk to targets on the distal side of cellular barriers.
84
 Sood 
and co-workers demonstrated that nanoparticles can cause indirect DNA damage in 
vitro across trophoblast and corneal barriers, and cause cytokine and chemokine release 
across corneal barrier. This indirect effect depends on the thickness of the cellular 
barrier through a pathway that involves gap junctions.
85
 Serag et al. demonstrated that 
the traffic of single wall carbon nanotubes (SWCNTs) into different cell subcellular 
structures can be facilitated or inhibited by attaching a specific functional tag and by 
controlling medium components.
86
  
 
Most of the nanotoxicology studies are based on understanding the acute response of 
nanomaterial exposure. However, the impact of chronic exposure of nanoparticles on 
human health is an important factor that should be taken in consideration. Recently, 
Mahler and co-workers showed the effects of oral exposure of polystyrene 
nanoparticles on the absorption of iron by using an in vitro model of the intestinal 
epithelium as well as an in vivo chicken intestinal loop model, demonstrating that acute 
exposure can disturb iron transport.
61
 Recently it has been shown that acute zebrafish 
embryonic exposure of nanoparticles could be used as a model to predict potential long 
term effects. Troung et al. exposed 1.5 nm gold nanoparticles (AuNPs) with different 
surface functionalization; negatively charged 2-mercaptoethanesulfonic acid and 
positively charged trimethylammoniumethanethiol (TMAT) and neutral 2-(2-(2-
mercaptoethoxy)ethoxy) ethanol (MEEE) to embryos showing that acute exposure of 
MES- and TMAT–AuNPs during embryonic development results in larval behavioral 
abnormalities that persist into adulthood and that was driven by the different surface 
functionalized gold nanoparticles.
87
 
 
In order to understand mechanism of the molecular pathogenesis in the mouse spleen 
caused by TiO2 NPs, Sang et al. exposed mice to 2.5, 5, 10 mg kg body weight of TiO2 
NPs for 90 days and investigated the inflammatory and immunological responses and 
apoptosis in the mouse spleen. They found that following exposure for 90 consecutive 
days disrupted the immunological function and toxicity in the spleen of mice, 
concluding that long-term exposure to low dose of TiO2 NPs could cause chronic 
splenic injury in mice.
88
 In addition, in a recent in vivo study, Sun and coworkers 
investigated the mechanism by which TiO2 NPs activates, Nrf2, in the mouse lung by 
exposing mice to 10 mg/kg body weight of TiO2 nanoparticles for 15–90 days. They 
founded that TiO2 NPs accumulated and increased the reactive oxygen species (ROS) 
production in lung provoking severe pulmonary edema, inflammatory response and 
pneumonocyte apoptosis.
89
 Cui et al, evaluated the gene expression profile in the livers 
of mice exposed to 10 mg/kg body weight TiO2 NPs for 90 days. Their results showed 
that titanium accumulated in the liver, and liver damage caused by long-term exposure 
to TiO2 NPs may be associated with significant changes in the expression of genes 
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involved in immune and inflammatory responses, apoptosis, oxidative stress, and the 
metabolism process, and in particular, a reduction in complement factor  expression. 
90
 
 
Understanding which of physicochemical properties of engineered nanomaterials leads 
to cytotoxicity remains a challenge, as these parameters are interconnected. 
91
 
Therefore, there is a need to develop new approaches to further evaluate the 
interactions and toxicology effects of nanomaterials with relevant biological systems. 
The following section will discuss the impact of physicochemical properties of the 
nanomaterials on their cytotoxicity.  
 
 
1.2.2 Role of the physicochemical properties  
Understanding which of the physicochemical properties of engineered nanomaterials 
determines their toxic response, uptake, and biodistribution in living organisms is not 
straightforward and still needs to be improved.
92
  Numerous studies have attempted to 
address this issue. Nevertheless, a brief overview on how the intrinsic physicochemical 
properties of nanomaterials affect cytotoxicity and how they can be tuned to control 
toxicity, uptake, and fate, are discussed in the following. The physicochemical 
properties of nanomaterials include size, shape, surface chemistry, rigidity, colloidal 
stability.
93
 
 
Size represents an important parameter to be considered from a toxicology point of 
view, as in case the size of nanoparticle decreases their surface area to volume ratio 
increases and will determine the number of surface groups present on the surface of the 
material and its reactivity.
94
 In general, for smaller nanomaterials a higher toxic 
response is observed.
6
 The role of size in particle uptake has been previously discussed. 
It has been suggested that for higher intracellular doses of nanoparticles a higher toxic 
response is observed.
92
 Furthermore, there are several in vitro studies showing size 
dependent uptake. For instance, Zhu et al. described size-dependent cellular uptake 
efficiency of silica NPs in HeLa cells.
95
 In addition, there are reports in the literature 
describing the effect of nanoparticle shape, and how this physicochemical parameter, 
can influence particle uptake and its mechanism. As well as size this feature affects the 
uptake of nanoparticles and biodistribution.
96
  In a recent study, Gliga et al. showed 
size-dependent cytotoxicity of AgNPs in human lung epithelial cells. However, in this 
study, the results indicated that intracellular metal release rather than differences in 
cellular uptake or intracellular localization was a probable explanation for the perceived 
differences in cytotoxicity.
97
  
 
Shape Awargal el al. evaluated the influence of shape and size of different 
polyethylene glycol diacrylate based hydrogel nanoparticles. They found that uptake 
was depending on the geometry of the particle and the cell model used. Based on the in 
vitro results, they hypothesized that intracellular uptake of NPs depends on three main 
factors, the sedimentation effect, directed by the weight of the NPs, the forces between 
the NP surface and cell membranes and the cell membrane strain energy necessary for 
membrane deformation around the nanoparticle. However in vivo evaluation is required 
   11 
to evaluate the in vivo relevance of the study.
98
 Another established example is carbon 
nanotubes, which are thought to exert toxicity due to their “needle-like” shape, that 
allow them to penetrate cell membranes. This may be relevant at least for multi-walled 
carbon nanotubes. 
99
 In addition, the differences in shape may affect particle clearance 
as well, as demonstrated by Barua et al. in a recent in vitro study, which spherical, disk 
and rod-shaped polystyrene nano- and microparticles were evaluated for uptake in 
human cancer cell lines.
100
  
 
When it comes to surface charge, in general positive materials give a stronger 
cytotoxic response compared to neutral or negative charged NPs. This may be 
correlated with their enhanced cellular uptake.  Indeed, positive NPs cause higher 
disruption of the plasma membrane integrity.
101
 Cationic PAMAM dendrimers have 
been associated with higher cytotoxic responses than non-anionic ones. The cationic 
response of PAMAMS appears to be generation dependent, which is associated to a 
different number of amino groups on the surface.
44,102
 Controlling and balancing the 
density of cationic groups on the surface of the nanomaterials can be used to minimize 
toxicity, which would be beneficial for specific biomedical applications.
103
 In general, 
neutral or negative surface charge nanoparticles showed prolonged blood circulation 
time and higher EPR, than  positive charge  nanoparticles, that are more toxic and 
induce higher  inflammatory reaction than anionic or neutral nanoparticles.
104
 Another 
example is illustrated the distinct hydrophilicity/hydrophobicity of graphene oxide 
(GO), where it was shown that the different surface oxidation states modulate their 
cellular uptake, gene regulation and toxicological response in HepG2 cells. Overall, the 
GO appear to be internalized whereas, reduce GO was adsorbed and aggregated at the 
cell surfaces with lower uptake.
105
 
 
Colloidal stability determines the dispersion stability of the NPs, and it is an important 
physicochemical characteristic, which directly affects toxicity. Okuda-Shimazaki et al. 
demonstrated the importance of the aggregation state and revealed that larger 
aggregates of TiO2 NPs (596 nm) were more cytotoxic than smaller aggregates (166 
nm) upon exposure to THP1 cells. 
106
  In this particular example, the findings suggested 
that the surface characteristics were more important for cytotoxic effects than the size. 
Wick et al. also illustrated the role of agglomeration on the cytotoxic effect of 
nanomaterials by using carbon nanotubes as a model nanoparticles.
107
 Balasubramanian 
et al. showed the role of the primary size of particles on the biodistribution by exposing 
rats to airborne Au NP agglomerates of primary size of 7 and 29 nm. They showed that 
the smaller agglomerates of Au NPs were distributed in more organs than the bigger 
ones.
108
 
 
In order to evaluate the benefits of using nanomaterials in medical applications we 
should consider the possible exposure risk and understand their biodistribution. 
Nanoparticles can cross biological barriers and enter and distribute within cells by 
different pathways.
109
 For that reason, they are considered a primary vehicle for 
targeted therapies. In the body we can find i) cellular barriers, including cell membrane, 
endosome, lysosome, and intracellular trafficking, and ii) physiological barriers 
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including blood, liver, spleen, kidneys, immune system, and the barriers that prevent 
extravasation of foreign substances from the blood. There is a concern for the risk of 
nanoparticles to translocate to organs and tissues and to cross different barriers. 
3
 
Understanding the barriers imposed by a biological system is critical for the design of 
new materials for biomedical application.
110
  Several studies have raised concern about 
the possible translocation of nanoparticles in the body.  For instance, Choi et al. 
synthesized a series of near-infrared (NIR) fluorescent nanoparticles to determine how 
their physicochemical properties affect their biodistributions, clearance and their 
translocation. Their result showed that nanoparticles with hydrodynamic diameter less 
than 34 nm with non-cationic surface charge translocate rapidly from lungs to regional 
lymph nodes in rats following intratracheal instillation. Moreover, nanoparticles with 
an hydrodynamic diameter less than 6 nm were able to traffic from the lungs to lymph 
nodes and the bloodstream and cleared by the kidneys.
111
 Schleh et al. by using 
different sizes gold nanoparticles with different surface charges (positive and negative),  
showed  that size and surface charge of gold nanomaterials  govern absorption across 
intestinal barriers and accumulation in secondary the organs after oral administration in 
a healthy rat model.
112
 
 
The rapid clearance of circulating particles during systemic delivery is a major 
challenge for diagnostic contrast agents and drug delivery systems in nanomedicine. 
Nanoparticle parameters such as size, shape, elasticity, surface chemistry, and shape are 
of particular interest since the effect of the delivery vehicles in the biological systems 
depends directly on these properties.
113
 
 
The evolution of the degradability of the nanomaterials is an important parameter to 
consider for their toxicity assessment and the future design of improved nanomaterials. 
Therefore, adverse effects may occur when nanoparticles are accumulated or cannot be 
biodegraded. Indeed, it is important that the degradation products are non-toxic. In 
accordance, Kagan et al. showed that single-wall carbon nanotubes could undergo 
biodegradation in vitro through human myeloperoxidase (hMPO), an enzyme present in 
neutrophils and in less degree in macrophages. Importantly, the enzyme degradation of 
nanotubes diminishes the potential of these nanomaterials to induce pro-inflammatory 
effects, as demonstrated in vivo.
114
 Moreover, it is necessary to evaluate systematically 
the toxicological effects of the intrinsic properties of the nanomaterials.  
 
 
1.2.3 Nano-bio interactions: the protein corona 
The nano-bio interface consists of the dynamic physicochemical interaction, kinetics, 
and thermodynamic exchanges between the surface of engineered nanomaterial and the 
biological constituents.
115
 When nanoparticles enter in contact with biological fluids 
they are immediately covered by proteins, forming what is known as “protein 
corona”.116 The proteins and other biomolecules which are adsorbed on the surface of 
materials directly affect the interaction between the nanoparticles and biological 
systems.
117
 Indeed, the protein corona critically determines the biological identity of the 
material. Therefore, a combination of both, i)  the  intrinsic properties of the materials 
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and their physicochemical properties, and ii) the biological identity as given by the 
protein corona, will dictate the biocompatibility, reactivity, biodistribution, and final 
fate of nanoparticles.
92, 118
  However, to be able to understand these biological effects, it 
is essential to characterize and identify the nature of the protein corona
119
. For that 
reason, although different studies have attempted to address this issue, more 
quantitative analysis is required, to provide new knowledge on the possible biological 
impact.
120
 Studies on protein corona formation of a well-defined in vitro system, where 
the effect of an individual protein was evaluated, indicated that under saturation 
conditions, the protein corona forms a single monolayer.
121
 This suggests that proteins 
bind on the nanoparticles in specific orientation.
122
 
 
As it has been stated earlier, protein corona formation is the primary occurrence at the 
interface between nanomaterial surfaces and biological fluids. In general, loosely bound 
proteins will form the initial soft corona driven by protein-protein interactions.
123
  
However, with time, a denser corona will be formed,
118
 which is strongly attached to 
the nanomaterial surface and which is formed by high affinity proteins.
116
  
 
Importantly, the corona formation is governed by the intrinsic properties of the 
nanomaterials, the ratio between nanomaterials and proteins, and the medium 
composition.
116
 Moreover, the formation of the protein corona appears to be a dynamic 
process
124
 that depends on the temperature, which directly influences its 
composition.
125
  There are studies indicating that the formation of the hard corona is an 
irreversible process.
126
 However, it is still unclear whether the protein-NP complexes 
may fluctuate depending on the NP environment. Importantly, further changes in the 
hard corona may occur when nanoparticles translocate from one biological 
compartment to another one.
127
 Liu et al. recently indicated that when nanoparticles are 
at the similar range sizes as proteins, the protein corona formation may be a reversible 
and unstable process as compared with protein formation on larger NPs.
128
 
 
One of the key challenges in nanomedicine is to design nanomaterials with the ability 
to target to specific tissues and cells.
129
 However, the physicochemical parameters that 
dictate the successful targeting of nanomedicines under in vivo conditions are still 
poorly understood. Indeed, whether the protein corona is able to mask the surface 
modification of nanoparticles and thus obscures the design of the synthetic identity 
remains to be further investigated.  Salvati et al. explored the role of the protein corona 
formed in fetal bovine or human serum on the targeting capabilities of transferrin 
conjugated nanoparticles.
130
 For this fluorescent silica nanoparticles coated with 
polyethylene glycol (PEG) and functionalized with human transferrin were synthetized. 
To this end, A549 cells expressing the transferrin receptor were used as a model 
system.  The result of their study demonstrated that the specific targeting ability of 
nanoparticles was lost in the presence of serum. Notably, the overall uptake of bare 
PEG silica nanoparticles (without transferrin functionalization) was higher than that of 
the target nanoparticles. Whether this situation will occur in vivo needs to be further 
evaluated.
130
 The biodistribution of nanoparticles in the body will be significantly 
dependant on their interaction with plasma proteins.
131,132
 Is known that nanoparticle 
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surface, size, and characteristics determine the binding properties of plasma proteins, as 
well as their effect in biological systems.
116
 Blood plasma coronas are sufficiently 
stable that they, rather than the nanomaterial surface, will be the surface that the cell 
may “see.133  Consequently, the protein corona may have an impact on immune cells 
and macrophages.
134
  Mononuclear phagocyte system (MPS) plays an important role in 
clearance of nanomaterials. One of the principal roles of phagocytic cells is to 
recognise and clear foreign materials. For that reason, strategies to modify 
nanomaterials to moderate their residence time in vivo have been suggested. Coating of 
nanoparticles with polymers such as PEG is a common approach. Indeed, PEGylation 
presents an important tool to prolong the blood circulation times
135
. 
 
There are studies showing the successful outcome of nanomedicines designed with 
targeting strategies. For instance, Rodriguez et al. showed the beneficial use of a “self 
peptide” CD47, attached to streptavidin-coated polystyrene beads. CD47 is a marker of 
“self” that is express in cell membranes, that cancer cells employ to inhibit macrophage 
mediated obliteration. The authors showed that the functionalized nanoparticles 
successfully modulated their clearance rate in vivo. The protein increased the 
circulation time of nanoparticles by delayed macrophage-mediated clearance and 
enhanced drug delivery to tumors in mice.
136
  
 
 
Figure 4: Synthetic and biological identities of nanomaterials. The image is reproduced from Fadeel 
et al.
92
 with permission from. © 2013  Wiley Periodicals, Inc  
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Furthermore, it has been shown that phagocytic cells are able to sense and recognize 
the self-peptide as a “non-eat me” signal. Konduru et al. successfully reported the use 
of SWCNTs coated with a phosphatidylserine as an “eat-me” signal, to make this 
material recognizable by different phagocytic cells once they are administrated.
137
  In 
addition, Kunjachan et al. evaluated the benefits of active versus passive tumour 
targeting using 10 nm sized polymer drug nanocarriers to target tumor blood vessels. 
The authors found that long-term levels of target nanoparticles where lower than the 
control polymers, suggesting the potential of active over passive tumor targeting in 
short circulation times. However, in the case of long-circulating nanomedicines, 
targeting effects should not be overemphasized.
138
 
 
There are studies addressing the effect of surface coatings on the protein corona and 
their role in cell uptake and recognition. For instance, Simberg and co-workers 
demonstrated that the surface of dextran-coated iron oxide nanoparticles could be 
recognized by macrophages, despite the plasma corona formation. 
139
 Furthermore, 
Kunzmann et al. reported that the uptake of SPIONs by primary human immune-
competent cells was determined, in part, by the nature of the surface coating
140
.  
Association of drug delivery systems with blood proteins is considered one of the most 
critical factors that determine the biodistribution, efficacy, and toxicity of 
nanoparticles.
141
 Lartigue  et al.  investigated the interaction of nanoparticles with 
blood plasma proteins and if they are concentration dependent.  Nanoparticles in 
contact with low plasma concentrations formed clusters, whereas nanoparticles in 
contact with higher plasma concentrations were coated and stabilized. Their results 
demonstrated that differences in coating directly dictated macrophage uptake.
142
   
Nanoparticle based drug delivery systems have been developed to improve the efficacy 
and reduce the systemic toxicity of drugs.
143
  Whether the active targeting in relevant 
fluids will be achieved/ disturb needs to be further investigated.  
 
 
1.2.4 Systems biology and predictive toxicology  of nanomaterials 
In  2007 the National Academy of Science proposed the so called “Toxicity Testing in 
the  21
st
 Century” report144. This paradigm was based on the need for new strategies for 
toxicity assessment, with the aim to shift from descriptive toxicology endpoints to more 
predictive toxicology approaches by using high throughput in vitro screening assays 
and computation tools, while minimizing animal tests.
145
 Collins et al. further 
emphasized the need for a shift from in vivo animals experiments to in vitro test using 
lower organisms, high content techniques, and computational modelling.
146
 In recent 
years, increased interest in developing rapid and comprehensive toxicology screening 
tools to predict the human toxicity in response to compounds has been raised.  
 
High-throughput screening (HTS) is a method for scientific experimentation that 
comprises the screening of large chemical libraries for activity against biological targets 
via the use of automation, miniaturized assays and large-scale data analysis. 
147
  The 
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use of HTS techniques have emerged as a useful tool to predict effects of 
nanomaterials, providing faster, repetitive, systematic, and quantitative data of new 
materials. HTS approaches could aid to rapid assess hazards of different engineered 
nanomaterials.
77
  
 
Toxicology assessment of nanomaterials is expensive and time-consuming, therefore, 
additional experimental approaches, such us the in-silico methods have been found to 
be important models to predict the potential toxicity of new nanomaterials.
6
 
Quantitative structure–activity relationship (QSAR) method used to predict the 
physicochemical properties of chemical compounds can be applied to predict metal 
toxicity of nanoparticles.
148
 There are currently only few nano-QSAR modelling 
studies. George et al reported the use of a HTS assay to test the cytotoxicity of metal 
oxide nanoparticles in cells.
149
 In a subsequent study, the authors combined the 
established HTS assay with in-silico tools to compare in vitro hazard to in vivo 
toxicological effects in zebrafish. Their results determined that the method was able 
to identify hazard and activity relationships through linkage to in-silico analysis 
tools.
150
  Moreover, Puzyn et al. established a model to describe the cytotoxicity of 17 
different types of metal oxide nanoparticles to Escherichia coli. The authors found 
that the model was able predicts the toxicity of metal oxide nanoparticles.
148
 
Furthermore, a biological surface adsorption index (BSAI) was established. The 
BSAI approach evaluates   the adsorption properties of nanoparticles by quantifying 
the competitive adsorption of a set of small molecule probes onto the nanoparticles.
151
  
Xia et al. using the BSAI approach  the determined that the nanomaterials clusters 
according to their surface adsorption properties.
152
  
 
The “omics” technologies provide information on the whole genome, with the 
advantage to characterize mostly all members of a family of molecules (such as DNA, 
RNA, proteins, etc.) in a single analysis,  enabling researchers to investigate with a 
global approach instead of the traditional “one gene at the time” approach.153 With 
these new tools, one can address biological enquiries by understanding the biological 
systems as whole.
154
  Toxicogenomics refers to the study of toxicology using 
techniques that elucidate how genomes respond to a toxicant or compound. 
Toxicogenomics approaches aim to use the new global “omics” analysis technologies 
such as transcriptomics, proteomics, metabolomics, lipidomics, and epigenetics, to 
provide evaluation of cellular molecular changes caused by chemicals and other 
environmental agents, with the benefit to move away from animal testing to mode-of-
action based in vitro tests.
155
  This technique relies on the computational tools to 
analyse, process, and interpret the enormous amount of data generated, that all 
together will provide comprehensive information to elucidate molecular mechanisms 
and specific cellular pathways that have been affected, and identify patterns or 
signatures related to a compound or toxicity.  
 
Systems Toxicology is expected to provide information on the dynamic interaction 
between molecular components of biological systems and how a determined compound 
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could disturb these interactions.
156
 It will provide information about the possible 
mechanisms, for both, compounds and nanomaterials, which will give new insights 
useful for risk assessment. (cf. Figure 5) 
 
Systems toxicology has four main areas of interest.
156
 i) To analyse the data obtained 
by the high-throughput methods, ii) to represent the relevant mechanisms of action, iii) 
to identify the biological responses (quantifying the dose-and time response 
perturbations) and iv) to build and validate the predicted computational model, with the 
final goal to use the information for risk assessment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Systems Toxicology. The image is a adapted  with permission from Sturla et al.
156
 Copyright 
(2014) American Chemical Society. 
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As recently discussed by Andersen et al. one of the primary focus upon the exposure of 
a compound/chemical substance to cells or tissues is to rather identified biological 
pathways instead of observing only the toxicity itself.
157
 This is also relevant for the 
toxicity of nanomaterials.  
 
There are only limited system biology studies on nanomaterials. In an elegant 
example of the use of proteomics and bioinformatics assessment by GO-based 
annotation, Tsai et al.
51
 revealed that gold nanoparticles can cause cell death through 
the induction of endoplasmic reticulum (ER) stress in the human myeloid leukemia-
derived cell line K562. In a recent study Chatterjee et al. evaluated the effects of two 
commonly used graphene nanosheets, graphene oxide (GO) and reduced graphene 
oxide (rGO) in human hepatoma HepG2 cells using global gene expression and 
pathway analysis. Their results showed that the distinct oxidation states of grapheme 
regulated their nano-bio-interaction effect, which was observed in the cytotoxicity 
studies and, in the global gene expression data. Indeed, omics approaches indicated that 
GO trigger the TGFβ1 mediated signalling pathway whereas rGO might cause host–
pathogen interaction and innate immune response through TLR4–NFkB pathway. 105  
 
ToxCast, a project of the National Center for Computational Toxicology at the United 
States Environmental Protection Agency was created to develop methods to predict 
human toxicity of chemicals utilizing in vitro assays, computational chemistry, high-
throughput screening (HTS) and various toxicogenomic approaches.
158
 A number of 
different reports attempted to implement the same paradigm on nanomaterial risk 
assessment. Intelligent testing strategy (ITS) allows the risks of nanomaterials to be 
performed in an accurate, effective and efficient manner.
159,160
 The ITS-NANO 
project was launched in 2012 to allow development of an ITS for nanomaterials 
safety.
160
 This approach has been used in other ongoing European Union projects 
including FP7-MARINA (see www.nanosafeycluster.eu). Overall, Systems Biology 
and HTS-based predictive toxicology approaches have been suggested as emerging 
methods to evaluate the bio-nano interaction between nanoparticles and living 
organisms.
161
 Therefore, in the coming years we expect to implement system biology 
as a tool to identify possible hazards of nanomaterials. 
 
 
 
 
 
 
 
 
   19 
2 AIM OF THE THESIS  
 
 
The overall aim of the thesis project is to understand the potential hazards effects of 
engineered nanomaterials and to evaluate their interactions with biological systems, in 
particular, assessment of potential immunotoxicity in order to develop optimal 
nanomaterials for biomedical applications. The specific aims of the study are: 
 
 
- to evaluate the biocompatibility and stability of a library of library of 
hydroxyl functional bis-MPA dendrimers on immune cells (primary human 
monocyte derived macrophages and cell lines) 
 
- to evaluate the effects of non-acutely cytotoxic PAMAM dendrimers in 
human bronchial epithelial cells using systems biology approaches 
 
- to synthesize novel superparamagnetic iron oxide nanoparticles and evaluate 
the biocompatibility in primary human monocyte derived macrophages to be 
used in biomedical application such contrast agent for magnetic resonance 
imaging 
                                                                  
- to study the biocompatibility in primary human macrophages and targeted 
uptake of  iron oxide nanoparticles with different surface coatings in ovarian 
cancer cells.  
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3 MATERIALS AND METHODS 
 
In this thesis, different methodologies have been used to efficiently characterize the 
nanomaterials and evaluate their toxicity impact on different cellular models, including 
primary immune competent cells. Detailed information regarding synthesis of the 
materials and methods used are described in the paper I-IV. The methods used can be 
divided in to two sections; synthesis and characterization of the nanomaterials and in 
vitro toxicity assessment. For material synthesis and characterization different 
instrumentation has been used for; i) synthesis ii) determination of particle size, iii) 
surface are and charge, iv) determination of chemical composition. For in vitro studies 
we utilized; i) microscopy techniques, such us TEM, ii) Cytotoxicity assays, including; 
viability, necrosis, mitochondrial function iii) uptake studies, iv) different cellular 
assays, including cell cycle, transfection, protein corona, cytokine detection, protein 
corona iv) bioinformatics analyses. 
 
Detailed description of the materials and methods used in our studies can be found in 
the publications and manuscripts included in the thesis. The sections below provide an 
overview of the methods used.  
  
3.1 MATERIAL SYNTHESIS 
3.1.1 Dendrimers 
Polyester bis MPA dendrimer 
Bis-MPA, TMP and hydroxyl functional aliphatic ester dendrimers of generation 1 to 5, 
and carboxylic functionalized 4
th
 generation Bis-MPA dendrimers were provided by 
Polymer Factory Sweden AB, Stockholm, Sweden. Dendrons were synthesized as 
described as previously reported.
35
 
162
  (Paper I).  
 
PAMAMs dendrimers  
PAMAMs dendrimers were purchased from Dendritech Inc., Midland, MI. 
 
3.1.2 Fluorescent labeling of dendrimers 
In order to monitor the internalization of dendrimers in cells, PAMAM-NH2 and 
PAMAM-OH were labelled with the fluorescent dyes, FITC and 5-DTAF, respectively, 
according to procedures previously reported. 
22 23
 Briefly, the labelled dendrimer 
solutions were dialyzed against distilled water through sterilized and rinsed membrane 
tubing for 24-48 h. Upon subsequent lyophilization, labelled dendrimers were obtained 
as yellow powders. The material was stored at -20ºC until further use. 
 
 
 
 
   21 
3.1.3 Magnetic nanoparticles 
 
Synthesis of the DHAA-Fe3O4 nanoparticles 
For the synthesis of DHAA-Fe3O4 nanoparticles, 0.1 M Fe(OH)3 colloid solution was 
first prepared by adding FeCl3·6H2O aqueous solution into 0.45 M NaHCO3 solution, 
and stirred for 30 min. Then, vitamin C water solution in a molar ratio to Fe
3+
 of 1:6 
was added progressively. The mixture was further stirred for another 10 min, and then 
transferred into a steel-lined Teflon autoclave with a volume capability of 50 mL. The 
autoclave was kept at 150 
o
C for 4 h. After the synthesis, the particles were washed 
with water and ethanol for 3 times and collected by centrifugation. The nanoparticles 
were then easily re-dispersed in water, PBS buffer and cell culture media by 
ultrasonication.
163
  (Paper IV). 
 
Synthesis of Fe3O4-SiO2-FA and Fe3O4-PEG-FA nanoparticles 
Fe3O4-PEG nanoparticles were synthesized following a slightly modified solvothermal 
process previously reported by Yan et al.
20
 Experimental details are provided in the 
paper IV. Core shell nanostructures were synthesized using a variation of the well-
known Stöber process. The synthetic pathway for Fe3O4-SiO2-FA particles and Fe3O4-
PEG-FA particles, and experimental details are provided in (Paper IV). 
 
 
3.2 MATERIAL CHARACTERIZATION  
3.2.1 Particle size and morphology  
High Resolution Transmission Electron and Scanning Electron Microscope 
High Resolution Transmission Electron Microscope (HR-TEM) and Scanning Electron 
Microscope (SEM) were used for imaging of the nanoparticles. The morphology, size 
and size distribution of the iron oxide cores and iron oxide nanoparticles were 
investigated using these techniques. For sample preparation refer to the original articles 
(Paper III and IV), Briefly, In paper IV,  the SEM images were obtained on a Zeiss 
NEON 40 Microscope and the TEM images on a Philips CM300 electron microscope 
accelerating a voltage of 120 kV, or the High Resolution (HR)-TEM instrument JEOL 
JEM 2100F (HR) with the acceleration voltage maintained at 200 kV. 
 
3.2.2 Surface area and charge   
Dynamic light scattering and zeta potential 
Dynamic light scattering (DLS) studies were undertaken to assess the hydrodynamic 
properties of the suspensions. The experiments were performed on a Malvern Zetasizer 
NanoZS instrument using a He-Ne laser at 633 nm. In paper II, PAMAMs were 
dispersed in phosphate buffered saline solution (PBS), deionized water and 
keratinocyte serum-free medium, prior to DLS evaluation. In Paper III, the 
measurements were performed in deionized (DI) water and in RPMI + 1% 
penicillin/streptomycin + 10% FBS cell culture medium. In Paper IV, the 
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measurements were performed in McCoy’s 5A medium cell culture medium with (+) 
and without (-) 10% fetal bovine serum non heat inactivated or in DI water using a 
concentration of 10 µg/ml NPs at 25°C. Size was determined by triple measurements 
with 10 scans in each measurement and averages are reported (Paper II, III and IV). 
 
 Z potential 
Zeta potential (ζP) is the electrical potential created between the charged surface groups 
of the particle and its surrounding medium, and provides information on the particle 
surface charge, an important parameter to evaluate in terms of material characterization 
since it will provide information on the interaction between nanoparticle and biological 
entities such as cells surface, proteins, etc. 
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 A Malvern Zetasizer NanoZS instrument 
was operated with a He-Ne laser at 633 nm and 25 °C. Zeta potential measurements 
were performed at 25°C on the NanoZS. In paper II, PAMAMs were dispersed in 
phosphate buffered saline solution (PBS), deionized water and keratinocyte serum-free 
medium. In Paper IV, the measurements were performed in McCoy’s 5A medium cell 
culture medium with (+) and without (-) 10% fetal bovine serum non hit inactivated or 
in deionized (DI) water using a concentration of 10 µg/ml NPs at 25°C (Paper II, III 
and IV). 
 
3.2.3 Chemical composition 
MALDI-TOF MS 
Characterization of the polyester dendrimers was conducted using Matrix Assisted 
Desorption Ionization Time of Flight (MALDI-TOF), one of the most common mass 
spectrometry techniques used for the characterization of dendrimers. Briefly, MALDI-
TOF-MS is used to obtain non-fragmented mass data of high-molecular-weight 
compounds.
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 The MALDI-TOF MS spectrum acquisitions were conducted on a 
Bruker UltraFlex MALDI-TOF MS with SCOUT-MTP Ion Source equipped with a 
N2-laser (337nm), a gridless ion source and reflector design. The detector mass range 
was set to 500-5000 Da in order to exclude high intensity peaks from the lower mass 
range matrix fragments. The laser intensity was set to the lowest value possible to 
acquire high resolution spectra. The obtained spectra were analyzed with FlexAnalysis 
Bruker Daltonics, Bremen, version 2.2 (Paper I). 
 
NMR spectroscopy 
Nuclear magnetic resonance (NMR) is one of the most frequently used techniques for 
the analysis of small molecules, polymers and dendrimers, including 
1
H NMR and 
13
C 
NMR. 
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 Briefly, experiments were performed on a Bruker Avance 400 MHz NMR 
instrument. 
1
H NMR spectra were acquired with a spectral window of 20 ppm, an 
acquisition time of 4 seconds, and a relaxation delay of 1 second. 
13
C NMR spectra 
were acquired with a spectral window of 240 ppm, an acquisition time of 0.7 seconds, a 
relaxation delay of 2 seconds. The residual solvent peak was used as internal standard 
(Paper I). 
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Assessment of dendrimer degradation 
In order to evaluate the stability of polyester dendrimers, The TMP-G4-OH dendrimer 
was dissolved in phosphate-citrate buffer of constant ionic strength (I=0.15 M) at 
various pH (pH 4.5, 5.5, 6.5, 7.5). For comparison, the TMP-G4-OH dendrimer was 
dissolved in 10 mL deionized water. The solutions were kept at 8°C, 20°C or 37°C and 
aliquots were taken at specific times for analysis by MALDI-TOF MS (Paper I). 
 
Fourier Transform Infrared Spectroscopy  
Fourier Transform Infrared Spectroscopy (FTIR) is a characterization technique that 
provides information on particle surface. FT-IR spectroscopy includes the absorption, 
emission, reflection, or photoacoustic spectrum achieved by Fourier transform of an 
optical interferogram.
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 In paper IV FT-IR spectra were measured with a PerkinElmer 
FTIR spectrometer in a range of 400-4000 cm
-1
. (Paper III and IV). 
 
X-ray powder diffraction  
X-ray powder diffraction (XRD) was used to characterization of iron oxide 
nanoparticles. XRD can provide information on crystal structure, crystallite size, and 
strain, x-ray diffraction patterns. 
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(Paper III and IV). In Paper IV the phase 
composition of the core material was characterized by X-ray diffraction using a STOE-
STADI MP with Cu Kα1 (λ = 1.5406 Å) radiation. 
 
Thermogravimetric analyses (TGA) 
In paper IV The mass of the conjugated FA was stated by thermal gravimetric analysis 
(TGA) using a TGA Q50 (IV Q50 (TA Instruments) instrument in a flowing air 
atmosphere with a heating rate of 10°/min. The UV-Vis spectra were recorded in water 
at room temperature on a Lambda 950 (Perkin Elmer) spectrophotometer (paper III and 
IV). 
 
Ultraviolet-visible spectroscopy  
The ultraviolet-visible spectroscopy technique measure the attenuation of a beam after 
it passes through a sample. In paper IV, the UV-vis spectra were recorded in water at 
room temperature on Lambda 950 (Perkin Elmer) spectrophotometer. 
 
Determination of iron content 
Total Fe was determined by inductively coupled plasma atomic emission spectroscopy 
(ICP-AES) on a Varian Liberty 220ICP. The suspension was prepared by combining a 
0.2 mL aliquot of the sample with 0.5 mL 8.8 N analytical grade HCl, and 1 mL 
deionised water. The mixture was heated to boiling and then immediately removed 
from the heat and allowed to cool to room temperature. The volume was adjusted to 50 
ml for spectrometric analysis (Paper III). 
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Elemental analysis (EA) 
In paper IV, to determine the elemental surface composition elemental analysis (EA) 
was performed by a CHNS EuroEA 3000 Analyzer from Hekatech. 
 
3T MR-imaging and relaxometry 
In paper III, MR-imaging and MR-relaxometry at 3T was performed in a clinical 
whole-body MR scanner (PHILIPS Achieva, the Netherlands) using a knee coil 
(SENSE-flex-M, PHILIPS, the Netherlands) at room temperature. Briefly, DHAA-
Fe3O4 water suspensions were diluted in deionized water at Fe concentrations ranging 
from 0.00017 to 1.25 mM. For MR measurements 0.3 mL/well of the diluted solution 
was filled in custom made phantoms. Furthermore, T1-, T2- and T2*-weighted images 
were acquired. For details, we refer to paper III. 
 
3.3 CELL MODELS 
3.3.1 Macrophages isolation and cell culture 
Macrophages are professional phagocytic cells and serve as a first line of defence 
against foreign intrusion. Peripheral blood mononuclear cells (PBMC) were prepared 
from buffy coats obtained from healthy blood donors by density gradient centrifugation 
using Lymphoprep as described before. 
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 Briefly, monocytes were positively selected 
based on CD14 expression using CD14 MicroBeads. To obtain HMDM, CD14
+
 
monocytes were cultured in complete RPMI-1640 medium, supplemented with 50 
ng/mL recombinant macrophage colony-stimulating factor (M-CSF) for 3 days. (Paper 
I-IV).  
 
3.3.2 Primary human bronchial epithelial cells 
The respiratory tract opens the external environmental directly into the airways. Indeed, 
bronchial epithelial cells are in first line of defence against infections and one of their 
main function is to recruit neutrophils by chemotaxis as an initial response to the entry 
of microbes. 
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  The establishment of the PBEC is described in detail in previous 
publications.
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 Briefly, cells were cultured in 80 cm
2
 plastic flasks at a density of (1–2) 
× 10
6
 in keratinocyte serum-free medium, supplemented with epidermal growth factor 
bovine pituitary extract and penicillin/streptomycin. The cultures were kept at 37 °C in 
a humidified atmosphere of 5% CO2 in air, and medium was changed every second 
day. At confluence, the cells were detached by exposure to trypsin/EDTA solution and 
reseeded in the desired plates and grown to 80% confluence. (Paper II). 
 
3.3.3 Cell line culture and differentiation 
HeLa cells 
HeLa, is the first continuous human cells line derived from a cervical cancer that was 
established in 1951
171
 from the cancer patient Henrietta Lacks. HeLa is a common cell 
model system used in scientific research. Cells were maintained in DMEM 
supplemented with 10% FBS, 1 mM Na-pyruvate, 100 U/mL penicillin, and 100 
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μg/mL streptomycin at 37°C in 5% CO2. Cells were counted and maintained in a 
logarithmic growth phase for all experiments (Paper I and IV). 
 
THP.1cells 
THP.1 is a human monocytic leukemia cell line established form the blood of a boy 
with acute monocytic leukemia in 1980.
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 Cells were cultured in RPMI-1640 medium 
supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 1 mM Na-pyruvate, 
5.0 × 10
−5
 M β-mercaptoethanol, 100 U/mL penicillin, and 100 μg/mL streptomycin. 
To induce differentiation into macrophage-like cells, 5.0x10
5
 cells/mL were stimulated 
with 150 nM PMA for 3 days at 37°C in 5% CO2. Cells were counted and maintained in 
a logarithmic growth phase for all experiments (Paper I). 
  
A549 cells 
A549 originates from a human carcinoma and was established in 1972 
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and is one of 
the most common in vitro model for a type II pulmonary epithelial cell found in the 
alveoli of the lung. Cells were maintained in DMEM supplemented with 10% FBS, 1 
mM Na-pyruvate, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37°C in 5% 
CO2. Cells were counted and maintained in a logarithmic growth phase for all 
experiments (Paper I). 
 
SKOV-3 cells 
SKOV-3 is a human ovarian carcinoma cells established in 1973 from a 64 year old 
female with an ovarian tumour. Cells were maintained in McCoy’s 5A medium 
supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL 
streptomycin at 37°C in 5% CO2. Cells were counted and maintained in a logarithmic 
growth phase for all experiments (Paper IV). 
 
3.4 CYTOTOXICITY ASSESSMENT 
3.4.1 Limulus Amebocyte Lysate (LAL) test 
Previous studies have highlighted the importance preparing endotoxin-free 
nanoparticles for biomedical applications,
174
 for that reason, nanomaterials were 
controlled for endotoxin contamination prior to incubation with cells. The chromogenic 
LAL test was used, that detect and measure the bacterial endotoxins in the samples 
such as Lipopolysaccharides (LPS). LPS is known to elicit immune response in animals 
and immune-competent cells. Briefly, the assay is based on the measurements of 
yellow colour, produced by the enzyme reaction, developed upon cleavage of the 
chromophore, p-nitroanyline, which is proportional to the amount of endotoxin 
concentration in the sample. The unknown concentrations of endotoxin in the samples 
are obtained in relation to a standard curve. The US Food and Drug Administration 
(FDA) mandated limits of acceptance for chromogenic LAL assays are 0.5 EU/mL). 
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176
 (Paper I-IV). 
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3.4.2 MTT assay 
Cell viability was assessed based on the mitochondrial conversion of 3-(4, 5-
dimethyldiazol-2-yl)-2, 5 diphenyl-tetrazolium bromide (MTT). MTT is reduced by 
dehydrogenase enzymes to insoluble formazan in the mitochondria of the living cells. 
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 Briefly, cells were seeded in 96-well plates and exposed to nanoparticles at the doses 
and time-points indicated in complete (10% FBS) or serum-free medium. Then, the 
supernatant was removed and cells were incubated with 100 µL of MTT solution (0.5 
mg/mL) for 3 h at 37°C.  The formazan (dark purple) is then solubilized with 50µl of 
dimethyl sulfoxide (DMSO), and the concentration determined by UV-vis at 570 nm. 
The percentage of mitochondrial function was calculated relative to untreated cells (cf. 
Papers I-II,IV). 
 
3.4.3 Alamar blue assay 
Alamar Blue assay was used to assess cell viability based on the reduction potential of 
metabolically active cells
178
. The assay utilizes Resazurin (7-Hydroxy-3H-phenoxazin-
3-one 10-oxide), a non-fluorescent blue indicator dye, that is converted to highly red 
fluorescent resorufin via the reduction reactions of metabolically active cells. Briefly, 
cells were seeded in 96 well plates and exposed to specific stimuli at the indicated time-
points. At the end of the treatment period, 10 µl of AlamarBlue® reagent was added 
and incubated for 2-4 hours at 37ºC. The fluorescence was measured at 560 nm 
excitation and 590 nm emission wavelengths. Since the amount of fluorescence 
produced is proportional to the number of living cells, the metabolic activity (cell 
viability) of treated cells was expressed as percentage versus the control (Paper II). 
 
3.4.4 LDH assay 
Cell viability was assessed base on the measurement of the release of lactate 
dehydrogenase (LDH), 
179
, a cytoplasmic  enzyme used as a marker of loss of plasma 
membrane integrity. Cells were seeded in 96-well plates and exposed to nanomaterials 
at the doses and time-points indicated. Then, 50 μL of supernatants were assayed for 
LDH activity following the manufacturer’s protocol. Results are presented as % 
Cytotoxicity = Experimental LDH / Maximum LDH release and related to untreated 
cells (Paper I-IV). 
 
3.5 CELLULAR UPTAKE OF NANOPARTICLES  
3.5.1 Transmission electron microscopy 
TEM was used to evaluate interaction of nanoparticles with cells. TEM is able to 
provide information of morphology of the cell upon nanomaterials exposure, and to 
visualize nanomaterial (both primary particles and agglomerates) and their intracellular 
localization. In paper IV, internalization of folic acid-conjugated iron oxide 
nanoparticles was assessed by TEM analysis. Briefly, HMDMs were exposed to 50 
µg/mL of nanoparticles and SKOV-3 cells to 10 µg/ml. At the indicated time-points, 
cells were harvested and samples were analyzed and visualized according to standard 
procedures. 
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3.5.2 Inductively coupled plasma-mass spectrometry (ICP-MS) 
ICP-MS is a high specificity and sensitive method that can detect analytes at a very 
low concentrations, (part per trillion).  For this reason, is an excellent sensitive 
quantification tool to evaluate the cellular uptake of nanoparticles upon proper 
digestion. However, we should take in account that ICP-MS cannot differentiate 
between adsorbed or internalized nanoparticles.
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 Quantification of the cellular 
content of iron was performed by ICP-MS, Briefly, 1.0x10
5
 SKOV-3 cells were 
seeded in FA-free medium and exposed the next day for 2 h to 10 μg/mL of 
nanoparticles in FA-free medium. Cells were then washed with PBS, counted and 
centrifuged at 1200 rpm for 5 min. Cell pellets were kept at -80 °C until further 
analysis. Measurement of iron content was performed using ICP-MS as described 
previously
5
 (Paper IV). 
 
3.5.3 Confocal microscopy 
Confocal microscopy was employed to monitor and visualize cellular internalization 
of FITC labelled PAMAMs. Briefly, PBEC and A549 were seeded in 24-well plates 
containing cover slips and allowed to attach for 24 h and were then incubated in the 
presence of labelled PAMAMs (0.1µM) in KSMF medium and (1µM) in DMEM 
medium respectively, for the desired time at 37 ºC. To determine the co-localization 
of PAMAMs with subcellular compartments, PBEC were incubated with labelled 
PAMAMs as indicated. Thirty min before fixation, Lysotracker (1 µM) or 
MitoTracker Deep Red FM (150 nM) was added. Slides were fixed with 4% 
formaldehyde, and mounted with DAPI-containing medium and visualized using a 
ZEISS LSM510META microscope (Paper II). 
 
3.5.4 Flow cytometry analysis of particle uptake 
The uptake of fluorescently labeled NPs can generally be quantified by flow cytometric 
analysis.
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 To study the internalization of FITC labelled PAMAMs, PBECs were 
exposed to the fluorescently labelled PAMAMs (0.1 µM) for the indicated time-points. 
Cells were then washed with PBS and incubated with trypan blue (250 µg/ml) (to 
quench extracellular fluorescence) for 5 min. Cells were then washed, centrifuged at 
800 rpm for 5 min, and washed again. Flow cytometry was performed using a 
FACScan equipped with a 488 nm argon laser (Becton Dickinson, San Jose, CA) 
operating with CellQuestPro software (Becton Dickinson) (Paper II). 
 
3.6 MEASUREMENT OF CYTOKINES 
3.6.1 ELISA 
Nanomaterial exposure could modulate normal immune function, for instance 
interacting with cells of the immune system, including phagocytes, that represents one 
of the first lines of defence against foreign organism and particles. Consequently, 
release of cytokines could occur.
132
 Cytokine secretion was studied as a functional end-
point in HMDM cells upon exposure to nanoparticles. Indeed, secretion of TNF-α, a 
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pro-inflammatory cytokine known to be released from activated HMDM was evaluated 
by the enzyme-linked immunosorbent assay (ELISA), an enzymatic assay that uses 
antigen – antibody reaction. Briefly, culture supernatants from HMDM were collected 
following nanomaterial exposure and kept at -80 ºC until cytokine analysis. TNF-α 
release was measured according to the manufacturer’s instruction. The absorbance was 
measured at 405 nm. Results were expressed as pg/mL of released cytokine using cells 
from different healthy blood donors.  
 
3.6.2 ELISpot 
Macrophage secretion of cytokines was assessed by enzyme-linked immunosorbent 
spot (ELISpot), a common assay to monitor immune responses in humans and animals. 
ELISpot assay measures cytokines secreted by cells at the single cell level. Briefly, 
cells are cultivated on a 96 well plate coated with a desired capture antibody. Upon 
stimulus, cells could secret cytokines, which successively will be captured by the 
specific antibodies on the surface. Indeed, to capture anti-cytokine antibodies for 
macrophage inflammatory protein (MIP)-1β, tumour necrosis factor (TNF)-α, 
granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-6, IL-
10 and IL-12 were diluted in sterile PBS to a concentration of 15 μg/mL and added to 
the plates. After incubation overnight at +4°C, unbound antibodies were removed by 
washing with sterile PBS followed by blocking for 30 min with complete cell culture 
medium. 500 or 750 hundred HMDM cells in 100 μL cell culture medium were added 
and co-incubated with nanoparticles at desired doses and time points. Cells were 
washed out with PBS and the plates were incubated for 2 h at room temperature (RT) 
with 100 μL/well of biotinylated antibodies to MIP-1β, TNF-α, GM-CSF,  IL-6, IL-10 
or IL-12  diluted to 1 μg/mL in PBS with 0.5% FBS. Then, the plates were washed in 
PBS and incubated for 1 h at RT with streptavidin–alkaline phosphatase diluted 1:1000 
in PBS with 0.5% FBS. Finally, the plates were developed with fresh filter BCIP/NBT 
substrate solution at RT until distinct spots emerged. The colour development was 
stopped by repeated washings with tap water. After drying, the spots were counted with 
an ELISpot reader using the AID ELISPOT software.
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3.7 SIRNA TRANSFECTION 
3.7.1 siRNA transfection 
siRNAs are simply internalized into cells with a siRNA transfection reagent. The 
success of gene silencing will depend on the correct delivery of siRNA. Transfection of 
SKOV-3 cells using specific siRNA against FOLR1 (Folic acid receptor alpha) was 
performed with Transfection Reagent  DharmaFECT1  according to the manufacturer’s 
protocol. A scrambled sequence was used as a negative control (Paper IV).  
 
3.7.2 Flow cytometric assessment of receptor expression 
Surface expression of FR-α on SKOV-3 was evaluated by indirect immunostaining 
using the anti-folate receptor antibody (2 µg/ml) followed by Alexa488 conjugated 
anti-mouse secondary antibody. Furthermore, non-specific fluorescence was monitored 
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using an isotype-matched control antibody followed by labelling with the secondary 
antibody. Flow cytometry analyses were performed using a FACScan operating with 
CellQuestPro software (Becton Dickson) (Paper IV). 
 
3.8 CELL CYCLE ANALYSIS  
PBECs and A549 cells were seeded at a density of 12 and 5.0 x10
4
 cells/mL, 
respectively in a 12-well plate and exposed to PAMAMs. After harvesting and washing 
with cold PBS, the cells were re-suspended in 500 μL Triton X-100 staining buffer to 
permeabilize the cells. Then, propidium iodide was added and cells were analyzed by 
flow cytometry within 30 min on a FACSCalibur (Becton Dickinson) operating with 
CellQuestPro software. MultiCycle AV (De Novo Software) was used for cell cycle 
analysis (Paper II). 
 
3.9 “OMICS” ANALYSES 
3.9.1 Transcriptomics 
mRNA sequencing data acquisition and pre-processing                                                                       
PBECs were exposed to PAMAMs and total RNA was extracted and purified from the 
cells and the samples were kept at -80°C until further use. The mRNA Seq of 
polyadenylated transcripts from total RNA (samples are purified by poly-A enrichment 
before library creation using Illumina Tru-seq RNA) was used to profile nanoparticle 
treated and control samples at the Science for Life Laboratory, Stockholm, Sweden. 
 
mRNA sequencing data analysis  
Counts from RNA sequencing, mapped to Ensemble gene identifiers (hg19), were 
processed and further analyzed using the R statistical programming language version 
3.0.2 (2013-09-25) and Bioconductor version 2.13 packages edgeR_3.4.1 and 
limma_3.18.4. Only genes that were differentially expressed between PAMAM-NH2 
and control as well as PAMAM-NH2 and PAMAM-OH were further analyzed. In 
addition, donor-specific effect ratios were calculated by normalizing filtered counts, 
offsetting the normalized pseudo-counts by 0.5 and log2 transforming them. Genes 
were filtered by requiring that from the PAMAM-NH2 vs. controls and vs. PAMAM-
OH, 5/6 (ratio) had to be in in the same direction. 
 
3.9.2 Bioinformatic assessment 
 
Gene Ontology enrichment analysis 
Gene Ontology (GO) categories describe how gene products behave in a cellular 
context: biological process: molecular function and intracellular compartment. GO 
enrichment analysis was performed with R/Bioconductor package topGO_2.14.0 using 
annotations from GO.db_2.10.1 and org.Hs.eg.db_2.10.1. Only gene categories which 
had a significance of p<0.01 and at least three significant genes are reported. 
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Pathway and upstream regulator analysis 
The regulatory networks and upstream regular analysis were generated using the 
Ingenuity Pathway Analysis (IPA) software (Ingenuity® Systems, 
www.ingenuity.com, Redwood City, CA, application version 220217, content version 
16542223). Based on the information data generated from millions of IPA tool 
generates molecular networks from the selected/interest genes.  
 
3.10 ASSESSMENT OF BIO-CORONA 
3.10.1 Isolation of the hard protein corona 
The preparation of nanoparticle protein corona  formation consists of three main  steps: 
i) preparation of the biological fluid (plasma or serum) ii) Incubation of NPs with 
biological fluid, iii) Separation of NP–protein corona complexes from excess of fluid 
by and washes to eliminate loosely bound proteins “ soft corona”183. In Paper IV, the 
hard corona proteins recovered from the iron folic acid conjugated iron oxide 
nanoparticles incubated with different % of FBS were compared by separation using 
SDS-PAGE gel electrophoresis. Briefly, to induce the formation of the protein corona 
at the nanoparticle surface, NPs were mixed with different FBS concentrations (1:10 
volume ratio) for 1 h at 37ºC. After incubation, the samples were centrifuged to pellet 
the nanoparticle protein complexes. The supernatant was discarded and the pellet was 
washed with PBS. Finally, after the last centrifugation, the pellet was suspended 
carefully with 100 μL of PBS buffer. Then, samples were incubated for 5min to 100 C 
to denature the proteins, cooled to room temperature, and loaded into a gel 
electrophoresis until the proteins neared. The gels were stained on the same day using 
the silver staining kit (Paper IV). 
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4 RESULTS 
 
4.1 PAPER I. STABILITY AND BIOCOMPATIBILITY OF A LIBRARY OF 
POLYESTER DENDRIMERS IN COMPARISON TO 
POLYAMIDOAMINE DENDRIMERS 
Dendrimers are polymer materials that could be design in a control manner to obtain 
specific, size, shape, density, branches, and surface functionality. Taken together this 
make these polymer structures optimal candidates for therapeutic applications. In Paper 
I, we investigated the stability and biocompatibility of different polyester dendrimers 
based on 2,2-bis(methylol)propionic acid (bis-MPA) in human cancer cells and primary 
human macrophages and compare them to polyamidoamine (PAMAMs) dendrimers. 
Dendrimers were synthesized as reported and thoroughly characterized by matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF 
MS), proton and carbon
 
nuclear magnetic resonance (
1
H, 
13
C NMR) spectroscopy
 
(
13
C 
NMR). 
 
In order to investigate the biocompatibility of the library of hydroxyl functional bis-
MPA dendrimers,  first we evaluated the mitochondrial function and plasma membrane 
integrity after dendrimer exposure to human cervical cancer (HeLa) cells and acute 
monocytic leukemia cells (THP.1) differentiated into macrophage-like cells,  and our 
results showed good biocompatibility at the time and dose used. Then, we evaluated 
their effects in primary human monocyte derived macrophages (HMDM) and 
compared with commercial PAMAMs with two different surface functionalization, 
amine and hydroxyl end groups respectively for comparison. Our findings 
demonstrated excellent biocompatibility for the entire hydroxyl functional bis-MPA 
dendrimer library to HMDMs, whereas the cationic, but not the neutral PAMAMs 
exerted dose-dependent cytotoxicity.  
 
Nanoparticles may have an impact on the functional responses of immune cells
168
, for 
that reson, we investigated whether dendrimers trigger cytokine release in HMDM by 
using the ELISpot assay. For that, we exposed dendrimers, dendrons to HMDM at 
doses of 10 µM for 24 h. Our results showed that no significant release of the pro 
inflammatory cytokines, TNF-α, IL-1β, IL-6, or GM-CSF, a growth factor for 
granulocytes and monocytes, or MIP-1β, a chemoattractant for monocytes and other 
immune cells, was detected in macrophages exposed either to bis-MPA dendrimers or 
PAMAMs, however LPS (0.1µg/mL) that was used as a positive control in the 
experiment, induce cytokines secretion in HMDM. 
 
In addition, the degradation rate of TMP-G4-OH dendrimer as a function of pH, 
temperature, and time was evaluated by MALDI-TOF MS. The stability was evaluated 
at the following parameters; pH 4.5, 5.5, 6.5 and 7.5 and at 8°C, 20°C and 37°C, and all 
preparations were prepared at a 100 µM and an ionic strength of 0.15 M. Our results 
showed that the bis-MPA dendrimers were degradable materials; indeed, TMP-G4-OH 
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dendrimers degraded more rapidly at physiological pH (7.5) when compared to acidic 
pH (4.5) (where no degradation was observed up to 40 days), demonstrating that the 
stability of the materials increases at low pH.  
 
In summary, we suggest that due to their excellent biocompatibility found in our in 
vitro studies, the hydroxyl functional bis-MPA dendrimers are promising materials for 
prospect biomedical applications. However, further in vivo validation is required to 
confirm these findings. 
 
 
4.2 PAPER II. NEXT GENERATION SEQUENCING REVEALS LOW-DOSE 
EFFECTS OF DENDRIMERS IN PRIMARY HUMAN BRONCHIAL 
EPITHELIAL CELLS: A SYSTEMS BIOLOGY STUDY 
While the toxicity of engineered nanomaterials are currently being extensively 
investigated using different in vitro systems, up today,  there are few studies addressing 
the effects of low doses of materials. To this end, we evaluated the effect of non-acutely 
cytotoxic doses of PAMAM dendrimers in primary human bronchial epithelial cells 
using a systems biology approach to predict the effects of these materials. Specifically, 
we evaluated the toxicogenomic profile of dendrimers by exposing primary human 
bronchial epithelial cells to Generation 4 PAMAM dendrimers with hydroxyl (-OH) or 
amino (-NH2) terminating groups using next generation sequencing (RNA-Seq). PBEC 
were exposed to PAMAMs at doses that did not elicit acute cytotoxicity. To this end, 
dose-response studies evaluating cell vitality and plasma membrane damage were 
conducted. Notably, PAMAM-NH2, but not PAMAM-OH elicited dose- and time-
dependent cytotoxicity in PBECs. Based on our results, we selected non-cytotoxic 
doses (at 48 h) for subsequent studies (0.1 µM). Next, we evaluated the internalization 
of fluorescently labelled PAMAM dendrimers by PBECs using flow cytometry and 
confocal microscopy. Our results showed that PAMAM-NH2 were more readily 
internalized when compared with PAMAM-OH and cellular uptake appeared to ensure 
through an active mechanism, as demonstrated by the reduction of uptake upon 
incubation with Cytochalasin D, an inhibitor of actin cytoskeleton polymerization. 
Furthermore, dendrimers were internalized and localized in lysosomes and not found 
either mitochondria or cell nuclei.   
 
Then, PBECs from three different human donors were exposed to not acutely cytotoxic 
doses of PAMAMs or medium alone for 48 h and subjected to whole gene 
transcription. The RNA-Seq data revealed that PAMAM-OH did not elicit any 
transcriptional responses while PAMAM-NH2 induced changes in gene transcription at 
the doses and time used. Overall, our statistical analyses indicate increased expression 
of 61 genes and decreased expression of 152 genes. In order to better understand and 
classify the transcriptional changes observed in PBEC upon exposure of PAMAM-
NH2, bioinformatics tools were employed.  Gene Ontology (GO) enrichment analysis 
was performed, markedly, the GO category for ‘cell division’ encompassing 47/152 
genes (p<10
-22
) was the most strongly down-regulated category. Notably, GO 
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categories with increased activities involved extracellular matrix disassembly, positive 
regulation of cell migration, and immune responses. Furthermore, Ingenuity Pathway 
Analysis of putative upstream regulators proposed that several genes were 
transcriptional targets of p53 and NF-kappaB.  
 
We therefore evaluated the effects of PAMAMs on cell cycle progression in PBEC 
since appear to be the most strongly down-regulated category. We found that 
PAMAM-NH2 impaired the cell cycle, with retention of cells in S-phase. Then, we 
investigated whether higher doses of PAMAM-OH could effect to cell cycle. Even 
when PBECs were exposed to higher doses or for a longer time (72h), PAMAM-OH 
did not cause cell cycle arrest.  Thus, suggesting that cell cycle arrest observed is 
related to surface functionalization of the PAMAM dendrimers. The upstream regulator 
analysis indicated that several of cell cycle-related genes were associated to NF-кB 
activation, then, we evaluated the role of NF-кB in cell progression. For that, PBEC 
were pre-incubated with a non-cytotoxic dose of Bay-117082 an inhibitor of NF-кB. 
Notably, Bay-117082 restored cell cycle progression in PBECs exposed to PAMAM-
NH2 as predicated by the upstream analyses. 
 
To this end, we evaluated whether PAMAM-NH2 are able to induce cell cycle arrest in 
another cell system, the human lung adenocarcinoma epithelial cell line A549. Notably, 
our biocompatibility studies revealed that A549 cells were distinctly less sensitive than 
the primary bronchial epithelial cells. Based on our cell dose response viability studies, 
we select non-cytotoxic dose (1 µM) to evaluate potential effects of PAMAMs on cell 
cycle progression upon exposure for 48 and 72 h. Our results showed that PAMAMs 
did not induce cell cycle arrest in A549. However, Resveratrol, known to cause 
accumulation of cells in S-phase, triggered retention of A549 cells in S-phase. 
 
In summary, the integrative approach presented in paper II, based on whole 
transcriptome sequencing using RNA-Seq and computation tools, have enabled the 
discovery and prediction mechanisms underlying cellular responses of non-acutely 
cytotoxic doses of PAMAMs to PBEC. The prediction was confirmed by in vitro cell-
based assays, demonstrating the benefits of system biology approaches in toxicology 
and risk assessment of nanomaterials. 
 
 
4.3 PAPER III. WATER-SOLUBLE SUPERPARAMAGNETIC MAGNETITE 
NANOPARTICLES WITH BIOCOMPATIBLE COATING FOR 
ENHANCED MAGNETIC RESONANCE IMAGING 
The aim of the study was to synthesize novel ultra-small superparamagnetic iron oxide 
nanoparticles (USIRONs) that could be used as negative contrast agents for MRI and to 
investigate possible toxic effects in primary human macrophages. USIRONs were 
synthesized by a simple hydrothermal method and were prepared by the chemical 
reduction of Fe(OH)3 colloid, by using vitamin C (a natural nutrient) as reducing agent 
under mild hydrothermal condition. This synthesis, provides a control and slow 
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condensation of the iron hydroxides that allows to obtain SUIRONs with superior 
physiochemical properties as compared with the traditional co-precipitation methods.
184
 
Indeed, the oxidized Vitamin C, the dehydroascorbic acid (DHAA), also acts as a 
stabilizer and allows the synthesis of water soluble iron oxide nanoparticles by a simple 
one-step method. 
 
Overall, USIRONs exhibit an average crystalline core size of (5.1 ± 0.5 nm). XRD 
measurements confirmed the nature of the iron oxide phase (cubic Fe3O4) and the TEM 
images illustrated that those nanoparticles have spherical shape and narrow size 
distribution. The hydrodynamic conditions were studied by DLS, and found that the 
average hydrodynamic sizes was 41 nm, bigger that the core size determined by XRD, 
TEM and magnetometry. Additionally, nanoparticles present a relatively monodisperse 
distribution with a PDI value of 0.12. Importantly, size, PDI and scattered intensity 
appear to be stable over time at different pH ranges. At the end, FT-IR was used to 
confirm the chemical transformation of vitamin C to DHAA. 
 
A comprehensive magnetic characterization was performed on USIRONs. The results 
showed that DHAA-Fe3O4 nanoparticles presented superparamagnetic properties with a 
saturation magnetization value of 47 emu g
-1
, a value higher than other described  iron 
oxide nanoparticles of similar size prepared by the solvothermal and high-temperature 
decomposition processes
185
. Furthermore, phantom experiments on the contrast agent 
(clinical 3 T MRI scanner) of DHAA-Fe3O4 suspensions revealed a relaxivity value 
ratio was r2/r1 of 36.4 (with r1= 5 s
-1
 mM
-1
 and r2= 182 s
-1
 mM-1), a value greater than 
clinically approved agents. Strong contrast was observed by T2 and T2*-weighted 
images giving evidence of the potential use of DHAA-Fe3O4 nanoparticles for 
biological applications, for instance, as a negative contrast agents for MRI. 
 
In order to evaluate the biocompatibility of the USIRONs, primary human monocyte-
derived macrophages were selected as a relevant model system, because when 
nanoparticles are intravenous administrated they may come in contact with immune 
competent cells. HMDM were exposed to different doses of DHAA-Fe3O4 
nanoparticles for desired dose and time, and cell vitality was assessed by the lactate 
dehydrogenase (LDH) release assay. Our results showed that cell viability of primary 
human macrophages exposed to USIRONs for 24 h was not affected as compared with 
ZnO used as a positive control. We further assessed the effect of DHAA-Fe3O4 on 
cytokine secretion (TNF-α) upon exposure to HMDM, and no cytokine release was 
observed in cells following incubation with USIRONs. 
 
In summary, we effectively synthetized a biocompatible  DHAA-Fe3O4 nanoparticle 
with narrow size distribution and long term colloidal stability with excellent 
superparamagnetic properties, that altogether, make these materials promising 
candidates for future medical application such as negative contrast agents. 
 
 
   35 
4.4 PAPER IV. TARGETED UPTAKE OF FOLIC ACID-FUNCTIONALIZED 
IRON OXIDE NANOPARTICLES BY OVARIAN CANCER CELLS IN 
THE PRESENCE BUT NOT IN THE ABSENCE OF SERUM 
Understanding the interaction of nanomaterials with proteins in a physiological 
environment is of considerable importance. In the present study, we synthesized folic 
acid (FA)-conjugated iron oxide nanoparticles with two different intermediate coatings, 
inorganic silica (SiO2) and organic polyethylene-glycol (PEG), respectively, and 
assessed biocompatibility and targeting efficiency using primary human macrophages 
and ovarian cancer cells. Indeed, we decided to investigate whether FA 
functionalization of NPs would lead to specific uptake by ovarian cancer cells, which 
were shown to express high levels of the folate receptor (FR)-α. 
 
Magnetic iron oxide nanoparticles (Fe3O4-PEG) with narrow size distribution and an 
average primary particle size of 18.4 nm were synthesized by solvothermal 
decomposition of iron salt in aqueous solution. The TEM and XRD measurements 
confirmed that phase structure of the iron oxide. Next, NPs were coated with either 
SiO2 or PEG. To form SiO2 nanoparticles, a ligand exchange with PVP in isopropanol 
was required.  For the subsequent functionalization of core-shell nanoparticles with FA, 
amino-propyl-tri-methoxy silane was used as the coupling agent. The TEM images and 
the FT-IR analyses evaluated the patterns of the core and shell phases and the silane 
linkers on the nanoparticles respectively, confirming the successful reactions. Finally, 
functionalization with FA was achieved by coupling the terminal amino groups of the 
Fe3O4-SiO2-NH2 nanoparticles previously obtained with FA using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) as a coupling agent. To form Fe3O4-PEG-
FA, Fe3O4-PEG particles were coupled directly to FA using a condensation reaction. 
The characterization data revealed that the primary particle sizes were 20 nm for Fe3O4-
PEG-FA and 80 nm for Fe3O4-SiO2-FA nanoparticles. 
 
Next, we evaluated their biocompatibility in primary human macrophages; overall, 
nanoparticles were shown to be non-cytotoxic at the time and doses used, as revealed 
by the mitochondrial function studies and TEM images. Subsequent, folate receptor 
alpha-mediated cellular uptake was investigated using ovarian cancer cell lines (SKOV-
3), which were shown to express high levels of the receptor. Nanoparticles were 
exposed to 10 µg/mL for 2h. The data indicated that the reduction of folate receptor-
alpha expression (using specific siRNA) resulted in a significant decrease in the 
internalization of the Fe3O4-SiO2-FA nanoparticles in ovarian cancer cells, whereas the 
uptake of Fe3O4-PEG-FA nanoparticles was not affected as evaluated by ICP-MS and 
TEM images. Notably, specific FA targeted uptake was only detected in the presence of 
serum proteins.  
 
PEG modification usually disrupts the protein adsorption; this could be the reason for 
that specific FR-α-mediated cellular uptake was observed only for Fe3O4-SiO2-FA 
nanoparticle. For that reason, we investigated the protein adsorption capability between 
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of the two nanoparticles to get a better understanding of their cellular uptake 
mechanism. For that, we evaluated whether the protein corona could be formed for both 
nanoparticles; Fe3O4-SiO2-FA and Fe3O4-PEG-FA were incubated with 10% or 55% 
FBS or in PBS alone for 1 h at 37°C and proteins recovered from the ‘hard’ corona 
were visualized by SDS/PAGE. Under these conditions, we found that the Fe3O4-PEG-
FA particles adsorbed serum proteins more abundantly than the Fe3O4-SiO2-FA 
particles.  
 
To conclude, we successfully synthesized for Fe3O4-SiO2-FA and Fe3O4-SiO2-FA core 
shell nanostructures using a variation of the well-known Stöber process with a narrow 
size distribution, presenting crystalline magnetic core. Interestingly we found that 
serum is required for folate dependent targeting to ovarian cancer cells. Due to their 
targeting capability and in vitro biocompatibility, Fe3O4-SiO2-FA nanoparticles are 
promising candidates for biomedical applications.  
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5 GENERAL DISCUSSION 
5.1 BIOCOMPATIBILITY OF NANOMATERIALS: TOWARDS PREDICTIVE 
TOXICITY TESTING 
Nanotechnology, nanotoxicology and nanomedicine are complementary disciplines 
that aim to provide future  novel and superior medicines.
76
 However, for the 
successful development and implementation of new design materials, it is essential to 
understand how the material intrinsic properties are linked to the physiological 
responses.
92
   
 
In order to increase our knowledge of how physicochemical parameters of 
nanoparticles affect biological systems, implementation of systematic and 
mechanistic in vitro studies is needed.
186
 In particular, it is important to assess how 
the intrinsic properties of the ENM (that will dictate their biological “identity” affects 
in immune system, which comprises the first line of defence again foreign 
materials
187
. Thus, part of the work presented here emphasizes the importance and the 
relevance of using primary human cells for the toxicity assessment of ENM. Primary 
cells maintain their phenotype in vitro and therefore a suitable model to closely 
mimic the in vivo situation. However, cell lines were also used, in particular for the 
assessment of targeting efficiency, and for reproducible systematic screening assays.  
 
Macrophages are one of the principal cells of the immune system, and represent the 
first line of defence against foreign materials including nanomaterials. Macrophages 
play important key roles in host defence, comprising phagocytosis, antigen 
presentation and immunomodulation. Notably, recent studies suggested that 
macrophages are mature differentiated cells with possible self-renewal capacity (local 
proliferation), similar to the capacity adopted by the stem cells.
188
 It will be important 
to determine the general mechanism of nanoparticle induce immunotoxicity, 
including i) recognition of nanoparticles thorough surface receptors, for instance Toll-
like receptors, ii) macrophages dysfunction, iii) inflammation responses such us 
induction of proinflamatory cytokines, chemokines and adhesions molecules  and iv) 
genotoxicity, such generation of oxygen radicals.
187
  The effects of nanoparticles on 
macrophages are still largely unknown. In this thesis, we carefully evaluated the 
possible immunotoxicity of dendrimers and SPIONs in primary human derived 
macrophages, as key cells of the innate immune system. The airway epithelium is the 
primary barrier for inhaled particles and compounds into the body, including 
particulate matter and airborne chemicals.
189
  For that reason, in paper II, primary 
human bronchial epithelial cells (PBEC) were selected as a model system as these 
cells play an important function in the innate immune defence against inhaled 
pathogens and particulates,
190
 and are involved in the recruitment of neutrophils by 
chemotaxis
169
 and in the cell clearance in the airways.
191
 
 
Engineered nanomaterials present a great potential for a wide range of medical 
applications. In the thesis, it was attempted to evaluate how different physicochemical 
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properties nanomaterials affect their biocompatibility, for their use in medicines. The 
nanomaterials evaluated are dendrimers and SPIONs, two different types of 
nanomaterials with great potential as drug delivery systems and imaging agents (MRI) 
respectively. 
 
In paper I, we evaluated the biocompatibility and stability of an entire library of bis-
MPA polyester dendrimers. This included the building blocks, core structures, as well 
as PAMAMs. Different methodologies have been used to efficiently characterize these 
nanomaterials and evaluate their possible cytotoxic impact on different cell lines and 
primary human macrophages. Overall, polyester dendrimers studied in this work 
exhibit excellent biocompatibility at the doses and incubation times used. 
 
In general, the successful translocation of dendrimers from laboratory bench to the 
clinic, will depend on their biocompatibility, reasonably fast renal elimination, and 
degradation rate.
192
 In addition, the efficacy of drug delivery systems will be also 
relying on their efficiency to deliver their cargo to the site of interest. In this context, 
the possible degradation of nanoparticles in lysosomes should be taken in account.
193
  
There are studies showing that PAMAM dendrimers enter cells by endocytosis 
194
. 
Within cells, the pH values of subcellular compartments may differ. Thus, the acidity 
increases sequentially from endocytic vesicles to early endosomes (pH=6.5), late 
endosomes, and lysosomes (pH˂5.5). 
195
  For that reason, in Paper I, we evaluated the 
stability of dendrimers in vitro at different pH values and incubation times by using 
MALDI TOF MS. We verified that hydroxyl functionalized bis-MPA dendrimers are 
degradable materials. Specifically, TMP-G4-OH dendrimers degrade faster at 
physiological pH (7.5) when compared to acidic pH (4.5). This demonstrates that the 
stability of the dendrimers increases at low pH.  
 
Nanotoxicology aims to identify potential health effects and mechanism of action of 
nanomaterials. However, careful understanding of nanomaterial physicochemical 
needed properties is desired for the future use of this material in medicine. Thus, 
extensive and systematic toxicological studies are needed it to build a comprehensive 
risk assessment of nanomaterials. For instance, Li et al.
196
 evaluated the role of surface 
functionalization and size of CNT materials, which were all obtained from the same 
pristine batch. A library of CNTs including carboxyl (-COOH,), polyethylene glycol (-
PEG), hexane diamine (-NH2), sidewall amine (-sw-NH2), and polyethyleneimine (-
PEI) functionalized multiwall carbon nanotubes (MWCNTs) was synthetized and well 
characterized. The in vitro studies were conducted in epithelial cells and macrophages. 
The study demonstrated the important role of surface charge in both toxicity, and 
cellular response. Indeed, anionic functionalization (-COOH and -PEG) decreased the 
pulmonary fibrogenic potential compared to as-prepared APMWCNTs. In addition the 
positive charge of cationic functionalization (-PEI) induced more pulmonary fibrosis. 
However, neutral and weak cationic functionalization (-NH2 and sw-NH2) showed 
intermediary effects.
196
 Furthermore, Li et al. recently synthesised a library of 10 rare 
earth oxide (REOs) NPs with an average size of 18–60 nm and studied their biological 
transformation in an acidic lysosomal fluid, as well as their impact in triggering lung 
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fibrosis. With this systematic approach, both in vitro and in vivo, the authors 
demonstrated that upon macrophage and lysosomal processing, REO nanoparticles 
undergo dissolution, leading to NLRP3 inflammasome activation, whereas pre-
treatment of REO NPs with phosphates in a neutral pH prevented biological adverse 
effects.
197
 These systematic studies were able to reveal the detailed mechanism of 
toxicity induced by these nanomaterials. 
 
In paper I, we evaluated a library of polyester bis-MPA dendrimers, to allow a 
systematic and comprehensive toxicity study. However, due to their excellent 
biocompatibility, no further mechanism of toxicity was contemplated.  In addition, in 
paper II, we investigated the effect of surface charge on the toxicity response of non-
acutely cytotoxic doses of PAMAMs to primary human bronchial epithelial cells. We 
observed that positively charged PAMAMs exhibit higher toxicity and higher uptake 
than the neutral PAMAMs, as previous reported also with other model systems.
198
 
199
  
 
 
5.2 SYSTEMS BIOLOGY APPROACHES FOR NANOMEDICINE AND 
NANOSAFETY  
Rapid growth in the field of nanotechnology involving novel synthesis of materials has 
emerged in the past few years due to the fact, that the novel physicochemical properties 
arising at the nano scale make ENM very attractive and promising for a wide range of 
applications. However, the increasing use of ENM rise the need to assessed the 
potential impact on human health and environmental. The effects of these new 
materials in human health are not well understood, as previously emphasized, 
nanotoxicology studies will give us references and guidelines to build and design new 
safe nanomaterials. Nevertheless, efficient and mechanistic toxicology tests are 
required to compare and predict the new paradigm for assessing the potential risk of 
these materials. System biology approaches together with in vitro high throughput 
screening (HTS) techniques will facilitate the development of new nanomaterials, by 
providing early prediction and mechanism information of cell interactions before 
moving to animal testing. The field of system biology is at an early stage but the goal is 
to use this approach and techniques to provide prediction of toxicity. With the 
implementation of these new tools, it will be possible to obtain toxicity data of 
thousands of nanomaterials, reduce the high time and cost of the animal testing: and 
facilitate development of safe nanomaterials. 
 
The potential impact of the nanomaterials on gene transcription has attracted 
considerable interest.
200 201
 However, studies addressing the effect of non-cytotoxic 
doses of ENM on gene expression profiling are rare. Although the toxicity of PAMAM 
dendrimers have been extensively reported, due to their potential use as nanomedicines, 
including; drug delivery, diagnosis and therapy,
202
 the molecular-level interaction 
mechanism and the cell pathways involved still not clear. We therefore, in Paper II, 
investigated the effects of non-cytotoxic doses of PAMAM dendrimers on gene 
expression in PBEC by using RNA-Seq and bioinformatics tools to identify biological 
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outcomes of these materials. Indeed, using system biology approach, we showed that 
PAMAM-NH2 and not PAMAM-OH prompted changes in gene expression profile as 
reveal by RNA-Seq and bioinformatics analyses. With the use of computation tools; 
GO and upstream regulator analyses, we predicted that these changes were induced 
through p53 and/or NF- кB dependent manner. Because GO analysis suggested that the 
genes that were affected upon exposure to PAMAM-NH2 primarily represented the cell 
cycle category, we assessed the cell cycle in PBECs exposed to PAMAMs dendrimers. 
Notably, low-dose exposure of cells to cationic PAMAMs, but not to PAMAM-OH, for 
48 h triggered cell cycle arrest, with retention of the cells in S-phase as anticipated by 
the of the systems biology-based predictions. Remarkably, Kim et al. reported that 
amino functionalized polystyrene nanoparticles induced cell cycle arrest in A549 cells 
was p53-independent. Therefore, it remains possible that different nanoparticles induce 
cell cycle arrest through different mechanisms.
203
 
 
Nanotoxicological studies are often based on the assessment of acute cytotoxicity, often 
using unrealistically high doses of materials. For future implementation of 
nanomedicine, more subtle effects occurring at low doses need to be addressed to better 
understand the toxicity of these nanomaterials. In Paper II, we have defined a “low” 
dose as a dose that does not cause acute cytotoxicity in the cell model used, PBEC. 
Notably, in Paper II, we were able to identify up regulation of gene related to immune 
systems such as TNF and MMP-9 and MMP-3, upon exposure of low doses of 
PAMAM.NH2 to PBEC. Interestingly, in a recent study of transcriptomic responses in 
zebrafish embryos, Oliveira et al. 
 
showed that PAMAM-NH2 (generation 3 and 4) 
caused transcriptional changes in zebrafish embryos at sub-lethal doses, consistent with 
the activation of the innate immune response. Specifically, PAMAMs induced 
expression of genes that are related to the innate immune response to bacteria including 
tnfb, irg1l, mmp9 and mmp13.
48
  
 
To date, few studies to date have applied system biology approach on nanomaterial-
exposed cells. In a recent study, Lucafo et al.
49
 evaluated the gene expression profile of 
human MCF-7 breast carcinoma cell line exposed to fullerenes using RNA-Seq 
technology. The bioinformatics analysis was followed by Connectivity Map (CM) 
analysis. CM identified similarities between the transcriptional signatures produced by 
fullerenes and those produced by other compounds with known modes of action. With 
this tool, the authors indicated that the gene expression pattern of fullerene-treated cells 
was similar to those induced by selective inhibitors of mammalian target of rapamycin 
(mTOR) signalling. Notably, in Paper II, when CM analysis was performed on our  
RNA-Seq data obtained in PBECs exposed to low doses of  PAMAMs, we observed 
that the gene expression profile of PAMAM-NH2 matched those of several compounds 
known to cause S-phase arrest (unpublished observation).  
 
Toxicogenomics  will move the traditional toxicology through the global observation of 
genomic responses to chemicals or substances
204
  and improve our understanding of 
mechanisms of toxicity.
205
 The combined application of the enabling omics 
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technologies with bioinformatics tools, will allow us to obtain more predictive 
information of mechanism of action of nanomaterials, as demonstrated in Paper II. 
 
 
5.3 THE BIOLOGICAL IDENTITY OF NANOMATERIALS AND ITS 
BIOLOGICAL IMPLICATIONS  
SPIONs are FDA approved nanomaterials for biological applications, such as contrast 
agents.
206
 However, the success of the new improved SPIONs is only accomplished if 
they present both, superior physicochemical properties and excellent biocompatibility. 
The main purpose of Paper III and IV was to synthetize new iron oxide nanoparticles 
with different surface coating, and to evaluate their effect on biocompatibility and 
mode of action of these materials at the nano-bio interface. 
 
The preparation of water dispersible iron oxide nanoparticles with proper surface 
coatings poses a challenge to nanomaterials synthesis. Therefore, in Paper III, stable 
aqueous USIRONs were successful synthetized by chemical reduction of Fe(OH)3 
using vitamin C as reducing agent. USIRONs presented excellent biocompatibility in 
HMDM, favourable colloidal properties, small hydrodynamic size, high r2 values, and 
desired relaxivity ratios for the enhanced contrast of T2- and T2*- weighted images. 
Overall, DHAA-Fe3O4 nanoparticles as described are estimated to be a promising 
candidate for negative contrast applications, such as MRI. 
 
Indeed, we emphasized the use of primary human macrophages in our studies, as 
important immune competent cells
188,207
  representing a more relevant in vitro model 
system than transformed cell lines. However, due to the promising target capabilities of 
the iron oxide nanoparticles synthesized in Paper IV, we used cancer cell lines to 
evaluate their targeting efficiency.  
 
In a physiological environment nanoparticles will be rapidly cover by proteins. The 
intrinsic properties of the nanomaterial will dictate the selectivity of the absorbed 
proteins on the surface, forming the so-called “biological identity” of the nanomaterials 
that will determine the interaction of the nanomaterials with living systems. The role 
and the effects of both, composition and dynamics of the protein corona in biological 
systems remain to be understood. It is known, that protein corona formation on the 
surface of nanomaterials is a dynamic process. However, the interaction that drives the 
proteins to assemble in biological scenarios is still not clear. Although several studies 
have attempted to address this issue, different conclusion could be drawn. This may be 
due to the different model used, including a variety of nanoparticles, biological media; 
experimental conditions, and techniques used. However, more systematic and 
quantitative characterization data of the protein corona could be obtained by simple 
analytical models to be able to provide comparative studies, to better understand the 
role of protein corona in the bio-nano interface.
120
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Active targeting aims to distribute drugs to the site of interest while minimizing the 
exposure to other tissues. It is suggested that surface functionalization of nanomaterials 
could be designed to enhance targeting properties. Gogary et al. synthetized FA-PEG-
PLGA vehicle nanoparticles able to passively and actively targeted folate receptors 
expressed on tumor cells. For that, various types of modified PLGA NPs were 
synthetized to evaluate the effect of PEG and FA in targeting capabilities of NPs. 
Uptake studies in HeLa cells showed that the FA conjugates enhanced the cellular 
uptake as compare with PEG-PLGA NPs. However, in vivo studies reporting FA-
targeted PLGA NPs encapsulating quercetin for cancer targeting and therapy reveals 
that uptake is enhanced by take place through both passive and active mechanism. 
208
 
 
The biological identity of the nanomaterial will directly affect the interaction with 
biological systems. In this thesis, we synthetized two FA-functionalized iron oxide 
nanoparticles with different surface coatings; Fe3O4-PEG-FA and Fe3O4-SiO2-FA and 
evaluated their biocompatibility and  the importance of particle coating for targeted 
uptake in ovarian cancer cells overexpressing folate receptor. It is important to note, 
that overall, only target uptake was achieved only for Fe3O4-SiO2-FA and not for the 
Fe3O4-PEG-FA and only in the presence of serum. Notably, we founded that both NPs 
are internalized in cells with or without silencing of FOLR1 receptor, suggesting that 
several uptake pathways may contribute to the internalization of nanoparticles. Our data 
suggested that the differences in targeting capability of the two nanoparticles could be 
related to differences in protein adsorption and/or agglomeration behaviour in the 
presence of serum. Although, PEGylation of the surface of nanoparticles is known to 
reduce protein adsorption and cell adhesion,
126
 our studies indicated that Fe3O4-PEG-
FA NPs adsorb higher amount of protein compared with Fe3O4-SiO2-FA NPs. Based on 
these results, we speculated that the targeting ligand of the Fe3O4-PEG-FA nanoparticles 
was not accessible for binding to the FR-α receptor on the ovarian cells due to the 
specific protein adsorption on the surface of the particles or that the ligand was trapped 
within PEG matrix and was not able to be recognized by the cells. Notably, the same 
studies were conducted on HeLa cells, which also express FA receptor. However, we 
could not find target specific uptake upon exposure of both nanoparticles, for that 
reason, we could suggested that the targeting capabilities of nanomaterials may not be 
only definite to a specific nanoparticle, but also cell type–specific. Finally, we 
highlight, that due to their targeting capability and in vitro excellent biocompatibility, 
Fe3O4-SiO2-FA nanoparticles are promising materials for medical imaging.  
 
The protein corona may alter the properties of the nanoparticle, thus need to be taken in 
consideration when study the biological interactions the nature of the nanoparticle 
surface is investigated.
116
  Walczyk et al. suggested that protein coronas rather than the 
nanomaterial surface are likely to be what the cell sees.
133
 However, it is unclear 
whether cell could also recognize the surface of the nanomaterial. In some scenarios, 
cell receptors may have preferences for the bare surface of nanoparticle. Simberg et al. 
showed that despite protein corona formation of SPIONs surface could be available for 
recognition by macrophages.
139
 To this end, the design future nanomedicines, it is 
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essential to understand the biological identity of the nanomaterials, especially for 
surface modified nanoparticles.  
Notably, a recent study by Salvati et al. indicated that excessive binding of serum 
proteins may impair selective, ligand-mediated uptake of nanoparticles.
130
 This effect 
may explain the results found for Fe3O4-PEG-FA, which appear to bind more proteins 
than Fe3O4-SiO2-FA.  
Nanoparticles are potentially useful for targeted drug delivery.
1
 Recent studies support 
the effective use of active targeting of nanoparticles, not only in animal models, but 
also in human cancer patients. Davis et al. conducted the first in-human phase I clinical 
trial involving the systemic administration of siRNA to cancer patients using a targeted, 
nanoparticle delivery system. By using transferrin antigen to target cancer cells 
overexpressing the corresponding receptor, the authors demonstrated the dose-
dependent accumulation of targeted nanoparticles in human tumours, and their 
consequently effective specific gene inhibition by a RNAi mechanism of action.
209
 
Furthermore, Hrkach et al. showed the beneficial use of a prostate-specific targeted 
polymeric nanoparticle containing the chemotherapeutic docetaxel for the treatment 
of patients with solid tumors.
210
 In a recent study, Pridgen et al. demonstrated that 
nanoparticles targeted to the neonatal Fc receptor (FcRn), which mediates the transport 
of immunoglobulin G antibodies across epithelial barriers, are efficiently transported 
across the intestinal epithelium using both in vitro and in vivo models. The specificity 
of the in vivo targeting was studied using FcRn knockout mice. Their results indicated 
that the nanoparticle transport was higher for target nanoparticles.
211
 
Interestingly, Caracciolo et al. showed that nanoparticles can acquire a targeting 
capability through the formation of a protein corona. Indeed, thus, lipid nanoparticles 
incubated in plasma were coated with vitronectin that promoted uptake in cancer cells 
expressing high levels of the vitronectin receptor.
212
  
Remarkably, the biological identity of nanomaterials “protein corona” could induce 
adverse effects in cells, such us inflammatory response. These possible effects should 
be taken in consideration for the future design of nanomedicines. Deng  et al. 
demonstrated that the hard protein corona, formed on the surface of negative charge 
gold NPs induced unfolding of fibrinogen proteins,  that were able to be recognized by 
cells though Mac 1 receptors, and  induce activation of an inflammatory process.
213
  
Moreover, Dobrovolskaia et al. investigated the role of nanoparticle surface properties 
and incubation times on the protein coronas formation using human plasma. For that, a 
series of 30 nm citrate stabilized gold nanoparticles with various molecular weights 
PEG were used and compared with bare NPs. Interestingly, their results showed that 
protein composition was not affected by either incubation time or PEG length, but the 
total amount of proteins was governed by the molecular weight of PEG coating. Protein 
binding was decreased with increased PEG molecular weight. The main conclusion of 
the study emphasized that corona formation did not predict hemocompatibility of 
NPs.
214
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The goal of achieving therapeutic efficiency of siRNA in the target tissue still remains a 
challenge. siRNA requires targeted delivery to be able to interact with the RNA 
machinery within the cells by passing through a variety of barriers. Sahay et al. 
evaluated the delivery of siRNA using lipid nanoparticles made by complexation of 
siRNA with the cationic lipid C12-200. Notably, about 70% of the internalized siRNA 
underwent exocytosis from HeLa cells through way out of LNPs from late 
endosomes/lysosomes. This previously unrecognized pathway suggested that new 
approaches for retaining siRNA inside cells are needed.
215
 
If we are able to understand and control these phenomena, in the near future, we may 
be able to design specific nanomaterials with desired intrinsic properties to be able to 
dictate the protein corona formation and harness it for various bio-medical applications. 
In conclusion, the application of nanotechnology in medicine is under development and 
nanomedicine is expected to provide new keys for unsettled clinical problems, and for 
that reason exhaustive toxicology studies should be performed in order to design smart 
and safe nanomaterials.
75
 Our studies have emphasized the importance of: 
 
- Using primary human cells as a model system to closely mimic the in vivo 
situation 
- Considering the effects of low doses of nanoparticles on cells 
- Applying system biology approaches in nanotoxicology research   
- Evaluating the effects of the protein corona on nanomaterials and  how 
different psychochemical proprieties such as size, surface charge, 
nanomaterial composition and the biological fluid determine its composition 
and targeting capabilities 
- Evaluating the intrinsic properties and the biological identity of NPs and their 
impact on biocompatibility, uptake, biodistribution and final fate of materials. 
 
Overall, our studies contribute to the development of new nanomaterials and their 
applications, which may facilitate clinical translation of nanomedicines. However, 
further studies should be directed to assess both the intrinsic properties and the 
biological identity of NPs and their impact on biocompatibility, uptake, biodistribution 
and in vivo fate. 
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6 CONCLUSIONS 
The following specific conclusions can be drawn from the presented studies (Paper I-
IV). 
 
Paper I  
 
- A library of hydroxyl functionalized bis-MPA dendrimers was effectively 
synthetized and characterized 
- Hydroxyl functionalized bis-MPA dendrimers present excellent 
biocompatibility in primary human monocyte-derived macrophages and cell 
lines, whereas the cationic, but not the neutral PAMAMs exerted dose-
dependent cytotoxicity in HMDM 
- Bis-MPA dendrimers are degradable materials and their stability increases at 
low pH 
- Due to their excellent biocompatibility, the hydroxyl functionalized bis-MPA 
dendrimers are promising materials for biomedical applications 
Paper II 
 
- Biocompatibility studies showed that PAMAM-NH2, but not PAMAM-OH 
elicited dose- and time-dependent cytotoxicity in PBECs 
- PAMAMs are localized in the lysosomes but not in the nucleus and appear to 
be internalized through an active mechanism 
- RNA-Seq analyses revealed changes of gene expression upon exposure of 
PBEC to non-acute cytotoxic doses of PAMAM-NH2 dendrimers  
- Gene ontology categories that are induced, are indicative of genes affecting 
cell cycle and division genes 
- Upstream regulator analysis indicated modulation of NF-kappaB and p53 
related  targets  
- Low doses of PAMAM-NH2 affected cell cycle in PBEC, by  arresting cells in 
S-phase in an NF-kappaB dependent manner 
- Whole transcriptome sequencing using RNA-Seq and computation tools, 
enabled to predict the uncover mechanisms of cellular responses of non-
acutely cytotoxic doses of PAMAMs to PBEC 
Paper III 
 
- Successful synthesis of novel ultra-small superparamagnetic iron oxide 
nanoparticles (USIRONs) was described by a simple one-step method 
- USIRONs exhibit an average crystalline core size of 5.1 nm and 
superparamagnetic properties with a saturation magnetization value of 47 emu 
g
-1
 
- Phantom experiments revealed that the relaxivity value of USIRONs r2/r1 was 
36.4, which is larger than clinically approved agents 
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- USIRONs are biocompatible materials as shown by the cytotoxicity studies in 
primary HMDM. 
-  USIRONs are promising candidates for future medical application such as 
negative contrast agents in MRI 
Paper IV 
 
- Effective synthesis of folic acid (FA)-conjugated iron oxide nanoparticles 
with two different intermediate coatings, inorganic silica (SiO2) and organic 
polyethylene-glycol (PEG), using a variation of the well-known Stöber 
process was conducted 
- Fe3O4-PEG-FA  and Fe3O4-SiO2-FA exhibit average sizes of 20 and 80 nm 
respectively 
- Nanoparticles were shown to be non-cytotoxic to primary HMDM. 
- Folate receptor alpha-mediated cellular uptake in ovarian cancer cell lines 
(SKOV-3) revealed that targeted uptake is only achieved for Fe3O4-SiO2-FA 
nanoparticles in the presence of serum  
- Due to their biocompatibility and targeting abilities, Fe3O4-SiO2-FA 
nanoparticles are promising candidates for biomedical applications 
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7 FUTURE PERSPECTIVES 
 
Advances in nanotechnology have given rise to the rapid development of novel 
applications in biomedicine, such as diagnostics, imaging and targeted drug delivery. 
However, their potential in biological scenarios is still not completely understood. 
 
Nanotoxicology is an interdisciplinary science, which requires the interaction between 
different disciplines, including material sciences and toxicological sciences. 
Nanotoxicology will provide us references and guidelines to build and design safe 
nanomaterials with specific properties, which will be available to achieve the current 
targets or specific medical approaches. The integration and combination of the different 
scientific competences will be essential for the successful design of future 
nanomedicines.   
 
We aimed to provide new knowledge about the interaction between engineered 
nanoparticles and primary human macrophages and cancer cells, in order to improve 
the design of these nanomaterials for biomedical applications. Novel, multi-functional 
nanomaterials for simultaneous drug delivery and imaging, using different imaging 
modalities are under development. Advances in this area will provide new knowledge 
of diseases such as cancer. Therefore, it is important to establish model systems for the 
evaluation of biological interactions and potential toxicological effects of such 
materials.  
 
Today, a proper risk assessment of nanomaterials is lacking. In order to map and 
characterise mechanistic pathways and molecular changes upon exposure to 
nanomaterials to human and health, additional approaches are required. Systems 
biology approaches combined with classical toxicity endpoint could help to identify in 
a global perspective, possible harmful effects of nanomaterials. Indeed comprehensive 
systematic investigations are essential to understand how nanoparticles (with specific 
physicochemical properties) interact with biological structures. Further studies in this 
area are needed. 
 
Indeed, we still do not completely understand the internalization process of 
nanoparticle in cells, and which are the relevant parameters that dictate the uptake 
mechanism and final fate in biological systems. Probably, they are governed by the 
intrinsic and the biological identity of nanomaterials. However, the exact factors are 
still undefined. If we could provide answers to this important question, we may be able 
to understand the efficacy of targeted delivery versus passive targeting. The effects of 
the protein corona on the targeting capabilities and toxicity response still remain an 
issue. Future studies should address the impact of the surface-adsorbed biomolecules of 
nanomaterials in biological systems. If we are able to understand this phenomenon, we 
may be able to design nanomaterial to modulate the “protein corona” formation. This 
fact may help us to design and obtain selective delivery of nanomedicines with high 
specificity.  
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Finally, omics approaches could be used as a tool to identify perturbations of cellular 
functions in response to nanomaterials, including responses not detected by 
conventional screening assays. New predictive nanotoxicology approaches, based on 
systems biology approaches may facilitate the identification of novel end-points of 
toxicity. 
In this thesis, we presented a system biology approach based on whole transcriptome 
sequencing coupled with computational methods to reveal key pathways involved in 
cellular responses to PAMAMs. Our studies demonstrated the feasibility of applying 
transcriptomics approaches to understand the effects of nanoparticles on cells. 
Therefore, to define and understand the possible hazard of nanomaterial, follow up 
studies using this methodology will be of particular interest. This is in line with the 21
st
 
Century Toxicology Paradigm, which emphasizes predictive, mechanism-based 
toxicology. 
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